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ABSTRACT 

Molecular Genetics of Arrhythmogenic Right Ventricular and Dilated Cardiomyopathy 
in South Africans 
Mzwandile Mbele 
Introduction: Little is known about the molecular genetics of cardiomyopathy in Africans. 
Aims: to (I) determine the prevalence of desmosomal gene mutations in arrhythmogenic right 
ventricular cardiomyopathy (ARVC) and dilated cardiomyopathy (OCM) in desmosomal 
protein genes (i.e., plakophyllin 2, desmocollin 2, desmoglein 2, and plakoglobin), (2) 
establish the presence of a founder effect in families with a recurrent mutation in the 
plakophilin 2 (PKP2) gene, (3) investigate whether single nucleotide polymorphisms found in 
desmosomal genes affect gene expression, and (4) search for new candidate genes for ARVC 
in families where no causal mutation was found in desmosomal protein genes. 
Methods: 177 participants with cardiomyopathy were screened for desmosomal gene 
mutations which were confumed by Sanger sequencing. The following methods were used: 
in the founder effect study we used haplotyping with microsatellite markers; for total gene 
expression we used real time polymerase chain reaction and allelic expression imbalance and 
exome sequencing was used for mutation screening in two siblings with severe early onset 
ARVC. To all novel variants identified prediction tools were used to predict the pathogenicity 
of the variant in uestion. 
Results: 21.5% of ARVC pro bands had a disease-causing mutation In one of four 
desmosomal genes; no disease-causing mutation was found in the 112 OCM index cases. A 
recurrent PKP2 mutation occurred on a common haplotype background in four white South 
African pfobands with cardiomyopathy. Investigation of a common PKP2 polymorphism had 
no effect on total gene expression nor was there evidence of allelic expression imbalance. 
Finally, rare mutations were found in PARVA and HMGXB3 by exome sequencing of two 
siblings. 
Conclusion: Oesmosomal gene mutations account for few cases of ARVC in South Africa but 
are a rare cause of OCM. The founder effect in PKP2 holds prospects for the creation of a 
panel of families to examine genotype-phenotype correlations in ARVC. Our work 
demonstrates the no differential impact of polymorphisms in desmosomal genes on gene 
expression in peripheral blood. Two rare, possibly deleterious, variants in PARVA were 
identified in ARVC probands. The identification of PARVA as a candidate gene fOf 
cardiomyopathy holds the prospect of a new diagnostic and therapeutic target for 
cardiomyopathy. 
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Chapter 1 
Molecular Genetics of Arrhythmogenic Right Ventricular and Dilated Cardiomyopathy 
in South Africans 
1.1 Background 
Overall mortality in the developed world shows the pre-emmence of cardiovascular and 
neoplastic conditions. By contrast, infective and parasitic conditions remain the dominant 
causes of death and disability in Africa. Although the causes of heart disease vary within and 
between African countries, the etiology remains largely non-ischemic, with hypertension, 
rheumatic heart disease, and cardiomyopathy being the major causes of cardiovascular 
disease, whereas tuberculous pericarditis and pulmonary healt disease account for the 
remainder (Sliwa and Mayosi 2013). 
The cardiomyopathies pose the greatest challenge of all the cardiovascular diseases in Africa 
because of their greater prevalence in societies still plagued by diseases of famine and 
pestilence, the difficulty in diagnosis, which often requires specialized cardiological 
investigations that are lacking in resource-poor environments, the lack of access to effective 
interventions, such as heart transplantation and the high mortality associated with these often 
irreversible disorders of heart muscle (Sliwa, Damasceno et af. 2005). Since the frrst reports 
of heart failure of unknown cause in Africa appeared approximately 60 years ago (Sliwa, 
Damasceno et af. 2005), it has been recognized that the entity of "cryptogenic heart disease" 
in Africa represented more than one syndrome, although terms such as "cardiopathy", 
"primary parietal endomyocarditis", "primary mural endocardial disease", and 
"cardiomyopathy" were initially used to embrace aJl forms of idiopathic heart disease. 
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The cardiomyopathies are now defined as myocardial disorders in which the heart muscle is 
structurally and functionally abnormal, in the absence of coronary artery disease, 
hypertension, valvular disease and congenital heart disease sufficient to cause the observed 
myocardial abnormality (Elliott, Andersson et at. 2008). They are divided into the following 
types depending on the structural and functional abnormality delineated by imaging: dilated 
cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy 
(RCM), arrhytlunogenic right ventricular cardiomyopathy (ARVC) , and unclassified types 
(Fig. 1.1). Each type of cardiomyopathy is classified into familiaVgenetic cardiomyopathy 
which defmes an occurrence of the disease in more than one family member or due to a de 
novo mutation and non-familial/non-genetic cardiomyopathy (Elliott, Andersson et at. 2008). 
" Disease ub-type' Disease sub-Iype" 
Figure 1.1: The European Society of Cardiology classification of cardiomyopathy (Elliott, 
Andersson et at. 2008). 
Familial cardiomyopathies are mostly monogenic disorders where a single gene defect is 
sufficient to cause the disease. De novo mutations are classified as familiaVinherited disease 
because the condition can be transmitted to the next generation. (Elliott, Andersson et al. 
2008). 
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The primary objective of is to delineate the 
cardiomyopathy and cardiomyopathy in Africa. 
are prevalent as hypertrophic cardiomyopathy, 
peripartum reviewed 
of arrhythmogenic 
of cardiomyopathy 
cardiomyopathy and 
and Mayosi 2013) (Sliwa, 
Damasceno et 2005) will not considered this 
1.2 Arrhythmogenic ventricular cardiomyopathy in Africans 
ARVC is of right ventricular 
in the presence 
(global or regional), with or 
without 
electrocardiographic 
evidence for the u,,,,-,a~'v 
published criteria (Marcus 2010). 
The histological hallmark of ARVC is the presence progressive replacement 
ventricular myocardium with adipose and confined to a of 
dysplasia' the right ventricular inflow, outflow and apex. While these 
abnormalities can result in functional and morphological right ventricular abnormalities, they 
occur ventricle, producing a phenotype, or can be present 
ventricle (Elliott, O'Mahony et al. 2010). 
Although uncommon (estimated ARVCisa 
death in people and athletes to re-entrant 
(La Gerche, Robberecht et al. 0). To the best of my 
reported the first time in Africa in 2000, approximately 40 years 
(Munclinger, Patel e{ al. 2000) and the possibility that 
this in South Africa, but under a different name that 
this in South 
congestive 
a different name, 
Torrington et 
cause sudden 
was 
case was 
have 
might have 
Hereditary 
"f.n.VM,,, ... n and Mntla 
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have subsequentl y reported a series of eight patients with isolated right ventricular 
cardiomyopathy who presented with symptoms of heart fai lure and no apparent arrhythmias; 
no special imaging, electrophysiological , or histological tests were perfonned to identi fy 
features of ARVC in these patients (Mokhobo and Mntla 1997). The prevalence and 
incidence of the disease in Africa is unknown. 
The death reports on ARVC in Africa are probably related to the lack of sophisticated cardiac 
electrophysiology facil ities and expertise required for the diagnosis of the disease (Millar and 
Mayosi 2003). Init ial infonnation from our ARVC Registry of South Africa suggests that 
ARVC occurs in all segments of the population and that its clinical features, frequency of 
fam ilial disease, and outcome are similar to experience that has been gathered elsewhere in 
the world (Watkins, Hendricks el al. 2009). 
The aet iology of ARVC is not ful1y unde rstood. The disease is familial in approximately 30-
50% of affected individuals and sporadic in the rest of cases (Lopes and Ell iott 2013, Te 
Rijdt, Jongbloed el al. 2013). It is thought th at a genetic or environmental insult causes 
cardiac ce ll apoptosis and replacement by fatty tissue or fib rosis. lnherited fonns of ARVC 
are caused mainly by mutations in desmosomal protein genes such as plakophi lin 2 (PKP2; 
locus 12p 11.21), desmoglein 2 (DSG2; locus 18q 12.1), desmocollin 2 (DSC2; locus 
ISqI2.1), desmoplakin (DSP; locus 6p24.3) and plakoglobin (JUP; locus 17q21.2). Figure 
1.2 illustrates desmosomal protein interactions that are involved in ARVC. Non-desmosomal 
gene mutat ions that have been implicated in ARVC have been found in desmin (DES; locus 
2q35), titin (TTN; locus 2q3 1.2), lamin Ale (LMNA ; locus Iq22), phospholamban (PLN; 
locus 6q22.3J), ryanodine receptor 2 (RYR2; locus Iq43), alpha T catenin (CTNNAJ , locus 
IOq21.3), and transmembrane protein 43 (TMEM 43; locus 3p25) (Te Rijdt, Jongbloed el al. 
2013). All these gene mutations are inherited in an autosomal dominant pattern with a few 
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cases in JUP and DSP inherited in an autosomal recessive fashion. Table 1.1 illustrates both 
desmosomal and non-desmosomal genes that were mapped and are involved in ARVC. 
o in 
Rr){! UCiP 
r-. .h: rminu 0 P 
DSP- Desmoplakin; DSC-2 - Desmocollin-2;JUP- Junctional plakogJobin;DSG-2 -Desmoglobin-2; 
PKP-2 - Plakopllilin-2 
Figure 1.2: Schematic of desmosomes structure (Sen-Chowdhry, Syrris et al. 2007) 
The molecular genetics of ARVC in Africans is largely unknown. There have been two 
reports on the molecular genetics of ARVC from the African continent. The first was by 
Matolweni and others who reported the linkage ofa large South Africa pedigree of European 
descent to the ARVC6 locus (Matolweni, Bardien et al. 2006). The causal genetic mutation 
has not yet been identified. The second report was based on my Masters thesis study of the 
first 36 participants in the ARVC Registry of South Africa which showed that PKP2 
mutations occur in about a quarter of patients with ARVC in South Africa (Watkins, 
Hendricks et al. 2009). 
The ARVC Registry of South Africa has subsequently been expanded to 65 cases of ARVC, 
and I report on screening for known and novel genetic causes of ARVC in this work. 
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Table 1.1: Loci and gene mutations that are associated with arrhythmogenic right ventricular cardiomyopathy 
(Rampazzo, Nava et al. 
1994 
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ARVC-2 (Rampazzo, Nava et al. 600996 Iq42-q43 AD 
1995) 
ARVC-3 (Severini, Krajinovic et al. 602086 I 14q 12-q22 I AD 
1996) 
ARVC-4 (Rampazzo, Nava et al. 602087 2q32.I-q32.3 AD 
1997) 
ARVC-5 (Ahmad, Li el al. 1998) 604400 3p23 AD 
ARVC-6 (Li, Ahmad et al. 2000) ; 604401 lOpl2-pl4 AD 
(Matolweni, Bardien et 
al. 
ARVC-7 (Melberg, Oldfors et al. 609160 IOq22.3 AD 
1999) 
ARVC-8 (Rampazzo, Nava et al. 607450 6p24 AD/AR 
2002) 
ARVC-9 (Gerull, Heuser et al. 609040 12pl1 AD 
2004) 
ARVC-IO (Pilichou. Nava el al. 18q12.1 ADNm 
Naxos I (Coonar, Protonotarios el 601214 17q21 AR 
, Cardiac Ryanodine Receptor 
I Unknown 
Unknown 
Transmembrane protein 43 
(TME. 
Unknown 
(Tiso. Stephan et al. 200 I) 
I 
I (Merner, Hodgkinson et al. 
Unknown 
Desmoplakin (DSP) (Rampazzo, Nava et al. 2002) 
Plakophilin-2 (PKP2) (Gerull, Heuser et al. 2004) 
Desmoglein-2 (DSG2) (Pilichou, Nava et al. 2006) 
Plakoglobin (JUP) (McKoy, Protonotarios el al 
al. 1998 
ARVC/APC I (Frances, Rodriguez 115650 I 14q24-q terminal I AR I Unknown 
Benitez et al. 199 
1.3 Dilated cardiomyopathy in Africans 
Dilated cardiomyopathy! DeM) is defined by the presence of left ventricular dilatation and left 
ventricular systolic dysfunction in the absence of abnormal loading conditions (such as 
hypertension or valve disease) or coronary artery disease sufficient to cause global systolic 
impairment. Right ventricular dilation and dysfunction may be present but are not necessary for 
the diagnosis (Elliott, Andersson et al. 2008). Dilated cardiomyopathy continues to be an 
important cause of heart :ililure contributing between 20% and 30% of cases of heart failure in 
adult Africans (Damasceno, Mayosi et al. 2012). 
The prevalence of DeM in the general population is unknown, but it clearly varies with age and 
geography. A frequency of 25% in patients from South African populations have evidence of 
familial disease with predominantly autosomal dominant inheritance (Ntusi, Wonkam et al. 
2011). Autosomal dominant forms of the disease are caused by mutations in cytoskeletal, 
sarcomeric protein! Z-band, nuclear membrane and intercalated disc protein genes. Table 1.2 
illustrates reported nuclear genes that are implicated in DeM. X-linked diseases associated with 
DeM include muscular dystrophies (e.g. Becker and Duchenne) and X-linked DeM (Watkins, 
Ashrafian et al. 2011). DeM may also occur in patients with mitochondrial cytopathies and 
inherited metabolic disorders (e.g. haemochromatosis). Examples of acquired causes of DeM 
include nutritional deficiellcies, endocrine dysfunction, HIV infection and the administration of 
cardiotoxic drugs. 
Dilated cardiomyopathy c,·n occur at a late stage following cardiac infection and inflanunation 
(Shaboodien, Maske et al. 2013). In contrast to active or fulminant myocarditis, which is, by 
definition, an acute inflanu natory disorder of the heart, often with preserved left ventricular size, 
inflammatory DeM is defined by the presence of chronic inflammatory cells in association with 
24 
left ventricular dilatation and reduced ejection fraction; histology and/or immunocytochemistry 
are, therefore, necessary for the diagnosis. A proportion of individuals with inflammatory DCM 
have persistence of viral proteins in the myocardium; viral persistence can also be observed in 
the absence of inflammation (Elliott, Andersson et al. 2008). 
Peripartum cardiomyopathy (PPCM) is a form ofDCM that presents with signs of cardiac failure 
during the last month of pregnancy or within 5 months of delivery (Sliwa, Hilfiker-Kleiner et al. 
2010). Suggested aetiological factors in PPCM include myocarditis, autoimmunity caused by 
chimerism of haematopoetic lineage cells from the foetus to the mother and the haemodynamic 
stress of pregnancy (Ntu:;i and Mayosi 2009). PPCM has also been shown to be part of the 
spectrum of familial DCM in about 7% of cases (Ntusi, Wonkam et al. 2011). PPCM can occur 
at any age but is more cc,mmon in women older than 30 years. It affects women of all ethnic 
groups, is almost equally associated with first/second and multiple pregnancies and is strongly 
associated with twin pregnancy and tocolytic therapy. 
Several association studie:; suggest that genes may playa role in the susceptibility to DCM in 
African populations. An a-;sociation with HLA-DRI and DRwlO antigens has been reported in 
South African patients, implying that genetically determined immune-response factors playa 
role in the pathogenesis of some individuals with DCM (Maharaj and Hammond 1990). A 
cornmon mitochondrial DNA polymorphism (T 16189C) has also been found to be a genetic risk 
factor for DCM in a South African cohort, with a population-attributable risk of 6% (Khogali, 
Mayosi et al. 2001). The association of the mitochondrial T l6189C mutation with DCM has 
been replicated in the British populations, suggesting that it is likely to represent a genuine 
genetic risk factor for DCM worldwide (Khogali, Mayosi et al. 2001). Mutation screening 
studies in patients with idi'Jpathic and familial DCM have identified a family with early-onset 
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DCM caused by a known mutation in the troponin T gene (Arg14ITrp) (Mayosi BM 2004), but 
there were no causal genetic mutations for DCM in cardiac and skeletal actin genes (Mayosi, 
Khogali et al. 1999). The investigation of the genetic association of ~ 1- and a2c-adrenoreceptor 
variants and the 0308A polymorphism of the tumor necrosis factor a gene with idiopathic DCM 
and the mitochondria DNA Tl6189C polymorphism with HIV associated cardiomyopathy have 
also proven to be negativ,~ in African patients (Badenhorst, van Staden et al. 2008, Brooksbank, 
Badenhorst et al. 2008, [)u Preez, Matolweni et al. 2008, Woodiwiss, Badenhorst et al. 2008, 
Shaboodien, Engel et al. 2009).Previously, positive associations were noted with regard to the 
aldosterone synthase gene and improvement in left ventricular ejection fraction in DCM (Tiago, 
Badenhorst et al. 2002), and the mitochondrial DNA Tl6189C polymorphism and HLA variants 
in increasing the risk of DCM as stated above (Maharaj and Hammond 1990, Sliwa and Mayosi 
2013). 
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Table 1.2: List of DeM reported genes (Arbustini, Narula et af. 2013) 
Emerin 
Eyes absenl4 
nger domain 
kmase 
LMNA 
LAMA4 600133 6q2 1 Laminin al pha 4 
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Table 1.2: list of reported DCM genes (Arbustini, Narula et al. 2013) (continue) 
7 
Myozenin 1 
Myopa 
lq31-q42 
IOq2 S.2 
3p21 
Sq33 .2 
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1.4 Overlap between the phenotype and genetic causes of ARVC and OCM 
It has already been mentioned above that ARVC may also be associated with left ventricular 
involvement in a si~~nificant proportion of cases. Indeed, there are instances when 
arrhythmogenic cardiomyopathy is predominantly left sided, in the entity that has been called 
arrhythmogenic left ventricular cardiomyopathy (Coats, Quarta ct at. 2009). Furthermore, the 
primary presentation of ARVC may be that of heart failure rather than an arrhythmia. 
Therefore the phenotype and presentation of ARVC may be difficult to distinguish from that 
ofOCM. 
The two cardiomyopathies have recently been shown to be caused by mutations in 
desmosomal protein genes (Elliott, O'Mahony et at. 2010). In 2002, ltoh-Satoh and his 
colleagues reported a genetic mutation in titin that causes OCM; mutations in the same gene 
have recently been implicated in ARVC by Taylor and his colleagues (Itoh-Satoh, Hayashi et 
al. 2002, Taylor, Graw ct al. 2011). There is therefore an overlap between the phenotype and 
molecular genetics of ARVC and OCM (Posch, Posch et at. 2008, Elliott, O'Mahony et al. 
2010). On the basis of this observation, I sought to determine in this work the prevalence of 
desmosomal gene mutations in South African patients with ARVC and DCM. 
1.5 Additional considerations in the study of the molecular genetics of cardiomyopathy 
in South Africa 
There are three factors that may playa role in the molecular genetics of cardiomyopathy in 
South Africa that have been studied in this thesis. The first is the possibility of the presence 
of founder genetic effects based on the population history of South African sub-populations 
that are over-represented in patients with ARVC. The second factor relates to the role of 
common polymorphisns in modifying the expression of genes that cause ARVC and OeM. 
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Finally, I sought to identify novel genetic mutations that may playa role in the pathogenesis 
of cardiomyopathy in South Africans. 
1.5.1 Founder effects in African heart diseases 
Previous reports have defined founder populations as the families with a disease allele 
descended trom the common ancestor (Brink and Schwartz 2009). In South Africa, genetic 
founder effects are common among the Afrikaner population which is predominantly of 
German, Dutch, and French origin. The founder effects in South Africa likely resulted from 
the fact that a small group of Dutch people harbouring a variety of rare, single gene diseases 
originally settled in the Western Cape Province in the 17th century (Moolman-Smook, De 
Lange et al. 1999) and later migrated to the rest of South Africa. Those single gene diseases 
have expanded in the Afrikaner population because of relative popUlation isolation due to 
perceptions of common origin, culture and religion (Brink and Schwartz 2009). Genetic 
founder effects have been observed among Afrikaners and South Africans of mixed ancestry 
in several heart diseases such as long QT syndrome (LQTS) (Brink and Schwartz 2009), 
progressive familial heart block type I and II (Fernandez, Moolman-Smook et al. 2005, 
Kruse, Schulze-Bahr ef III. 2009), familial hypercholesterolemia (Kotze, Langenhoven et al. 
1991, Kotze, De Villier~, et al. 1993) and HCM (Moolman-Smook, De Lange et af. 1999). 
Founder popUlations are not unique to Africa; they are also common in Finland where 
genetic founder effects have been identified in many diseases (Norio 2003) and also to many 
regions of the world. 
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1.5.2 Role of single nucleotide polymorphisms in gene expression 
Polymorphisms are defined as common sequence variations, which occur in coding; non-
coding regions of genes and can also occur in non genetic regions. with a frequency of> 1% 
in the general population (Matkovich, Van Booven et al. 2010). There are different types of 
polymorphisms including single nucleotide polymorphisms (SN Ps) and microsatellite 
polymorphisms. Both SNPs and microsatellites could regulate promoter activity and gene 
expression (Hassel, Dahme et al. 2009). They are also associated with a variety of diseases 
such as cancer and Crohn' s disease (Tuch, Laborde et al. 2010, Hu and Peter 2013), and are 
used as markers in founder effect studies (Hassel, Dahrne et al. 2009, Sheu, Zhai et al. 2009). 
SNPs may be homozygc,us or heterozygous, synonymous or non-synonymous or deletions or 
insertions. 
Understanding of the cellular mechanisms that modulate gene expression is required in order 
to define their genetic c,)ntribution to human phenotypic variations (Campino, Forton et al. 
2008, Cunnington. Kay ct a!. 2009). Cis regulatory elements are cis-acting factors which they 
regulate sequences to which they bind to are on the same DNA or RNA as the gene or RNA 
transcript that is being regulated (Strachan and Read 1999). Trans-regulatory elements might 
be located on different chromosomes and regulate both copies of the gene of which their 
expression levels can be affected by environment variables (Campino, Forton et al. 2008, 
Pham, Bonello et a!. 2(112). The effect of cis-regulatory elements on gene expression is 
investigated in this work through quantification of the allelic expression effects by the SNP of 
interest (Cunnington, Kay et al. 2009). 
A powerful approach to investigate allelic expreSSiOn imbalance (AEI) is to perform a 
quantification of the expression of transcripts obtained from each individual with 
heterozygous alleles (Beltelshees, Aquilante et al. 2012, Pham, Bonello et al. 2012). The 
approach is based on the fact that in the absence of allelic expression variation there will be 
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an equal amount of txpression from both the paternal and maternal alleles as they are 
exposed to same em ironment. In comparison. individuals heterozygous for cis-acting 
polymorphisms that affect gene expression or messenger ribonucleic acid (mRNA) 
processing will show all alteration in the level of mRNA expression from one allele compared 
with its partner allele and this variation is termed allelic expression imbalance (AEI) (Pham, 
Bonello et al. 2012). 
1.5.3 Novel genes that contribute to the disease phenotype 
The known genetic murations that cause ARVC (Table 1.1) explain about 50% of cases of 
ARVC (Basso. Corrado et al. 2012). It is likely therefore that there remain a number of novel 
genetic causes of ARVC that have not been discovered. The advent of new methods of 
sequencing, such as eXJme sequencing, has improved the chances of detection of causal 
genes in small families or individuals with inherited conditions (Yang. Muzny et al. 2013). 
Sanger sequencing and fluorescence-based electrophoresis technologies have been used to 
determine variants in somatic and germline genetic studies. To increase the throughput of 
Sanger sequencing, the llse of massive parallel sequencing was developed (Reis-Filho 2009, 
Ng, Buckingham el al. 2010). (Reis-Filho 2009. Ng. Buckingham et al. 2010). Massive 
parallel resequencing technology renders resequencing of the whole genome practical but 
cost remains an importa!1t consideration. Its approach involves the targeted sequencing of 
protein-coding sequences (exome sequencing) which was reported to require approximately 
5% as much sequencing f.S a whole human genome (Ng, Turner et al. 2009, Ng. Buckingham 
et al. 20 I0) Exome sequencing is reported to be a more efficient strategy to investigate for 
alleles underlying rare Mendelian disorders (Ng, Buckingham et al. 2010. Yang. Muzny et al. 
2013). Exome sequencing is part of the next generation sequencing technologies recently 
developed. which include Roche 454. lIIumina GA and ABI SOLID; these are considered to 
be more productive and less expensive as compared to Sanger sequencing (Harismendy, Ng 
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et al. 2009). An overview of exome sequencing technologies compared with Sanger 
sequencing is summarized in figure 1.3 below (Harismendy, Ng et al. 2009) . Exome 
sequencing for novel disease-causing mutations was carried out in this study because there 
are many cardiomyopathy families who did not show any gene mutations in known genes. 
P ooled LR-PCR ampllco,. 
.~ - -- .. .. - ~ .~ -~ - -- ---- ..-. Ind'''''",,--I SR--PCR ampkons 
.-. .:.:.:.:,:- ---­
-
- -' --- .._-.----------- .--......... 1 

-+ 
Roche 454 IIlumina GA ABI SaUD ABI Sanger 
... ... ... ... Roads 
procosslng 
Van ant 

callIng 

.. 
SR-PCR. shorl range PCR and LR-PCR: Long range PCR 
Figure 1.3: Comparison of exome sequencing with Sanger sequencing (Harismendy, Ng et 
al.2009) 
1.6 Aims of this study 
The aims of this study were: 
I) To determine the prevalence of desmosomal gene mutations in South African patients with 
ARVC and OCM; 
2) To investigate the existence of founder effects in the event that recurrent mutations were 
found; 
3) To detennine whether polymorphisms in desmosoma.1 genes influence total gene 
expression and allele-specific expression; 
4) To perform exome sequencing to identify known or novel gene mutations that causes 
ARVC in families with no desmosomal gene mutation. 
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Chapter 2 
MATERIALS AND METHODS 
This chapter provides a detailed outline of the materials and methods that have been used 
throughout this th.:sis. More details are provided in the appendices: appendix I is an 
approval letter froPl the ethics committee; appendix 2 is the desmosomal gene (Tables 1-4) 
and PARVA (Table 5) designed primers; appendix 3 is solutions and buffers and appendix 4 is 
the GeneRuler™ 1 OObp DNA Ladder Plus. The appendices are presented at the back of the 
thesis. 
2.1 STUDY PARTICIPANTS 
The cases recruited for this study are patients with arrhythmogenic right ventricular 
cardiomyopathy (ARVC) and dilated cardiomyopathy (DCM). 
2.1.1 ARVC Cases 
The ARVC cases were enrolled in the ARVC Registry of South Africa which was established 
by the Working Group on Registries of the Cardiac Arrhythmia Society of Southern Africa 
(CASSA), as reported previously (Latib, Michaels el al. 2004). The registry is approved by 
the Human Research Ethics Committee of the Faculty of Health Sciences of the University of 
Cape Town (Appendix I). Physicians refer suspected cases of ARVC and their first-degree 
relatives to the Coordinating Centre in the Cardiac Clinic, Groote Schuur Hospital, Cape 
Town, for consideration for enrollment in the registry. 
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A group of cardiologists from the Cardiac Clinic at Groote Schuur Hospital established a 
diagnostic panel thal reviews the diagnosis of each of the potential ARVC patients and 
determines whether they meet the diagnostic criteria for ARVC or not. A definite diagnosis 
of ARVC was made if the patient met the diagnostic criteria set by the Task Force of the 
Working Group on Myocardial and Pericardial Diseases of the European Society of 
Cardiology and of th,! Scientific Council on Cardiomyopathies of the International Society 
and Federation of Cardiology (McKenna, Thiene et al. 1994). If some of the criteria were met 
and no alternative diagnosis was found, a diagnosis of possible or probable ARVC was made. 
If there was no ev idence of AR VC and/or an alternative diagnosis was present. the case was 
considered not to have ARVC. The diagnosis of the first degree relatives of affected 
individuals was madt, based on the modified criteria of Hamid and colleagues (Hamid, 
Norman et al. 2002). 
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Table 2.1: The diagnostic criteria of ARVC 
IV Depolarization/ conduction 
structural alterations 
I Global and/or regional dysfunction and 
abnormalities 
Major Major 
Severe dilatation ard reduction of right Epsilon waves or localized prolongation 
ventricular ejection fraction with no (or only (>llOms) of the QR complex in right 
mild) LV imparement precordial leads (V \- V3) 
Minor Minor 
Mild global right ventricular dilatation and/or Late potentials (signal averaged ECG) 
ejection fraction reduction with normal left 
ventricle 
Mild segmental dilatation of the right 
ventricle 
Regional right ventricle Hypokinesia 
V Arrhythmias II Tissue characterization of the walls 
Minor 
Fibrofatty replacement of myocardium on 
Major 
Left bundle branch block type ventricular 
endomyocardial bie,psy tachycardia (sustained and non-sustained) 

(ECG, Holter and exercise). 

Frequent ventricular extrasystoles( more than 

1000/24h)(Holter) 

III Repolarization abnormalities . VI Family history 
Minor Major 
Inverted T waves ir right precordial leads Familial disease confirmed at necropsy or 
(V2 andV3)( people aged more than 12 yrs, in surgery 
absence of right branch bundle block) 
Minor 
Family history of premature sudden death 
«35yrs) due to suspected right ventricular 
dYsplasia 
2.1.2 DCM cases 
The DCM cases were recruited from Groote Schuur Hospital and LCT Private Hospital in 
Cape Town; Chris Hani Baragwanath Hospital, Milpark Hospital and Sunninghill Hospital in 
Johannesburg; Dr George Mukhari Hospital in Pretoria; as well as Inkosi Albert Luthuli 
Hospital in Durban. as reported previously (Du Preez, Matolweni et al. 2008). 
The diagnosis of DCM was based on the criteria from the European Society of Cardiology 
Working Group on Myocardial and Pericardial Diseases (Elliott, Andersson et al. 2008). 
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2.1.3 Controls 
Controls for genetk screening of gene variants comprised genomic deoxyribonucleic acid 
(gDNA) only and controls for total gene expression and allelic expression included gDNA 
and RNA. gDNA \\as used to genotype the SNPs of interest and RNA was used to study the 
expression of the ge'1e harboring the SNP. Three sets of population controls were used in this 
study: (l) the Cap.: Town population controls were used for the screening of genetic 
mutations that cause cardiomyopathy (Chapters 3 and 6) and (2) the South African population 
controls and the North East of England population controls were used in the study of gene 
expression and allek expression imbalance (AEI) (Chapter 5). 
2.1.3.1 Cape Town controls 
The Cape Town population controls were used to determine the population frequencies of 
novel variants identitied in desmosomal and other genes (Chapters 3 and 6). Two hundred 
and thirty two anorymous blood donors from the Western Province Blood Transfusion 
Service (WPBTS) p"ovided blood samples for DNA extraction. The blood samples were 
obtained from 99 people of mixed ancestry, 62 black Africans, I I people of Indian origin and 
60 white South Africans. 
2.1.3.2 North East England population controls 
The UK popUlation controls were recruited in hospitals based on the fact that they do not 
have heart diseases. They were included to the study for the comparison with South African 
cohort.These controls were used in the total gene expression and allele expression imbalance 
experiments (Chaptel 5). A total of 192 gDNA and RNA samples were obtained from 
anonymous individuals who participated in this study. They were all white persons who were 
born in the United Kingdom (UK). These anonymous individuals were recruited from two 
hospitals: the Freeman Hospital in Newcastle-upon-Tyne and the James Cook University 
Hospital in Middlesborough. 
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2.1.3.3 South Africa~l controls 
These controls wert: used to study tolal gene expression and allelic expression imbalance of 
variants in chapter 5. A different set of 307 blood donors from the WPBTS contributed blood 
samples from which gDNA and RNA were obtained. The participants included people of 
mixed ancestry (n 200), black Africans (n = 67), Indian South Africans (n = 30) and white 
South Africans (n = 10). The South African participants were the cohort of choice for allelic 
expression studies a:, they were expected to exhibit greater genetic diversity and higher allelic 
heterozygosity compared to European Caucasians who demonstrated low levels of 
heterozygosity in previous studies (Salisbury, Pungliya el al. 2003). The South African 
population controls were used to perform allelic expression imbalance (AEI) and the North 
East of England population controls were used to investigate total gene expression. 
2.2 DNA EXTRACTION AND QUALITY CONTROL 
2.2.1 DNA extractiol 
Peripheral blood samples were collected from participants in 5 ml ethylenediaminetetraacetic 
acid (EDTA) tubes. The samples were stored at -80°C until they were extracted. All blood 
samples were kept 2t room temperature for at least 2 hours prior to extraction. The gDNA 
was extracted from reripheral blood using the PureGene™ DNA isolation kit (Gentra system, 
USA) and was extrhcted according to the manufacturer's instructions. The gDNA samples 
were given disease lode numbers (ACM to refer to the disease ARVC) to anonymise them 
and were fi led in tile database of the Cardiovascular Genetics Laboratory at the Hatter 
Institute for Cardiovascular Research in Africa. Department of Medicine, University of Cape 
Town. 
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2.2.2 Quality Control 
The purity and concentration of gDNA were measured using a NanoDropTM ND-IOOO 
spectrophotometer (Thermo Scientific). All extracted gDNA samples were quantified at an 
absorbance of 260/280nm using a NanoDrop ND-2000 spectrophotometer (Thermo 
Scientific, UK) in I ~ I solution. All the gDNA samples were vortexed and spun down prior to 
measurement and each sample was measured twice for confirmation of its concentration. The 
average of two measurements was taken as the concentration of each sample. 
All gDNA samples were divided into long term stock solutions which were stored in a -80aC 
freezer; working stocks of DNA were made and used for experiments. For experiments, 
working stocks of DNA were made into aliquots of IOOul which were standardized to 
25ngllli and stored at 4°C. 
All primary DNA extractions were also validated using the QubitTM Fluorometer (Invitrogen. 
USA) which is con,idered an accurate determinant of nucleic acid concentrations. All 
samples were mixer by vortexing before concentration measurements were taken; the 
manufacturer's instrw:tions for measurement of DNA concentrations were followed. Samples 
were also run on 1.5~o agarose gels to check the integrity of the DNA (appendix 2). 
2.2.3 Agarose gel electrophoresis 
Agarose (Seakem® LE, Whitehead Scientific (Pty) Ltd, SA) was used to visualize the 
products of the polymerase chain reaction (PCR). It is a standard method for separation of 
PCR products. Agarose is cross-linked to form pores through which DNA particles migrate at 
different speeds depending on the size of the fragment. The PCR products migrate towards 
the cathode (positive terminal) in an electric field due to the negative charge of DNA. The 
velocity at which molt-cu les move through the agarose pores depends on the size of the pore, 
which is related to the percentage of the agarose in the gel. To visualize the PCR products in 
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the agarose gel, Ge1Red1M, a fluorescent nucleic acid stain, was used to stain the peR 
products. GelRed™ intercalates between the base pairs of the DNA strands and is visualized 
under ultraviolet (UV) light The loading of the DNA and the monitoring of electrophoretic 
progression were as~,isted with the electrophoresis buffer, I JlI of 1 X loading dye with a DNA 
ladder (GeneRulerH1 100bp DNA ladder Plus) (appendix 3) which was run alongside peR 
products to give the sizes of the peR products, which were electrophoresed through a 2% 
agarose gel in 1 X TAE buffer. 
2.3. POLYMERASE CHAIN REACTION (PCR) amplification 
2.3.1 Principle of peR 
The principle of the peR is based on the amplification of a target piece of DNA using two 
primers mediated by enzymes to generate thousands to millions copies of that particular DNA 
sequence (Mohini Joshi 2010). The technique of peR is widely used in molecular biology to 
amplify a section of gDNA. The technique uses oligonucleotide primers to anneal to specific 
gDNA template sequences which flank the genomic region of interest. A gDNA polymerase 
enzyme is used to extend the sequence from the primers across the target region in many 
cycles and each cycle consists of denaturation, annealing and elongation in order to produce 
numerous copies or the target sequence. With peR it is possible to generate millions of 
gDNA copies of interest for biological use (Santos, Sakai et al. 2004). 
2.3.2 Optimization (fthe peR conditions 
All the gDNA samples from patients under investigation were diluted to a concentration of 
25ng/ili. peR optimization was first performed on one gDNA control sample in a peR 
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gradient. The temperature producing the correct ampJicon size on an agarose gel was then 
selected. The desmosomal primers used are presented in appendix 4 (desmosomal gene and 
PARVA primers). 
PCR amplification was performed on a pre- PCR bench with pre-PCR pipettes to a total 
volume of 251-lJ. The reaction mixture contained: 25ng of gDNA, lX GoTaq ™ Flexi 
Buffer, 1.5mM MgCI 2, 0.8mM dNTPs, 0.5 I-lM of each of forward (F) and reverse (R) 
primers each and 0.5 Units (U) of GoTaq Flexi polymerase. The cycling conditions used 
during PCR are presented in Table 2.1. 
Table 2.2: PCR cycling conditions used for DNA expression in peripheral blood 
Temperature C€) Time Number of cycles 
94 15 minutes I 
94 30 seconds 
35Annealing temperature* 30 seconds 
72 90 seconds 
72 5 minutes I 
*Depends on annealing temperature of the particular amplicon 
PCR was run on the Peltier thermal cycler (Tetrad2). A negative control (whereby deionised 
H20 was used instead of DNA) was included in all PCR experiments. This was done to 
identify possible contamination that could interfere within the reactants. 
2.4 DESMOSOMAL SCREEN 
The mutation screening of four desmosomal genes (i.e. plakophilin 2 (PKP2), desmoglein 2 
(DSC2), desmocollin 2 (DSC2) and plakoglobin (JUP)) was performed using either the 
denaturing high performance liquid chromatography (dHPLC)-based WAVE@ system 
(Transgenomic, Inc., Omaha, NE) or High Resolution Melt (HRM) analysis with a Rotor 
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gene 6000 (Corbett Life Science) for mutation screening, followed by direct Sanger 
sequencing of abnormal amplimers on the screening test. The methods that were used were 
based on the screening technique that was in place in the laboratory. As the screening 
technology changed, so did our screening methods. The dHPLC technique was replaced by 
HRM technology about half-way through this study. All ampIicons larger than 300 base pairs 
were deemed unsuitable for HRM analysis and were directly sequenced. 
2.4.1 Denaturing High-performance Liquid Chromatography 
The principle underpinning the dHPLC-based WA VE® system (Transgenomic, Inc., 
Omaha, NE) is to separate heteroduplex gDNA fragments from homoduplex gDNA 
fragments by ion-pair reverse-phase liquid chromatography (Xiao, Stern et al. 2001, Frueh 
and Noyer-Weidner 2003). A heteroduplex is a double-stranded gDNA complex in which the 
two strands do not have perfect base complementarity and a homoduplex is a double stranded 
gDNA with perfect base complementarity (figure 2.1) 
w:ild-:1ype mi.rtalilt eteroduplexes :nomoduplexes 
heat 
0001 
+ 
A T GC G G T GC 
I I ~I ( I I 
A 
Figure 2.1: Illustration of the formation of both the heteroduplexes and the homoduplexes in 
the process of denaturing high-performance liquid chromatography (Frueh and Noyer­
Weidner 2003). 
The method detects all types of nucleotide mismatches regardless of the position of the 
mismatch in the fragment. The W A VE® system of dHPLC operates in three different modes: 
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partial denaturation, full denaturation and non-denaturation (Xiao, Stem et al. 2001, Frueh 
and Noyer-Weidner 2003) . This study utilised the partial denaturation mode, as it is 
appropriate for the sequence, size and the melting temperature (Tm) of the PCR products. 
Once the PCR products are loaded in the autosampler, they are passed through the separation 
cartridge during the mobile phase . For dHPLC two steps are necessary: PCR amplification 
and heteroduplexing. 
2.4.1.1 PCR amplification 
A total of 25 ilL of PCR reactions were prepared for certain DSC2 and PKP2 amplicons 
following the PCR methods mentioned above. gDNA from both cardiomyopathy patients and 
population controls was amplified and visualized on agarose gel as mentioned before or 
otherwise stated. 
2.4.1.2 Heteroduplexing ofthe PCR products 
The PCR products of gDNA samples of the individuals affected with cardiomyopathy were 
mixed in equal volumes (1: 1 ratio) with PCR products from the gDNA samples of control 
individuals. The mixture was denatured at 95°C for 5 minutes. 
2.4.1.3 Detection ofdesmosomal variants using a WA VE system 
After denaturation of the heteroduplex samples they were subjected to a WAVE system for 
the detection of sequence variants. DHPLC-based W A VE® system uses the Wavemaker 
software programme; the programme was used to create methods for mutation detection for 
each PCR amplicon. 
2.4.2 High resolution melt (HRM) 
The principle of HRM is based on the characterization of double stranded DNA according to 
its annealing behavior. The process is done by monitoring the annealing from double stranded 
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DNA to single stranded DNA with increasing temperature as explained below. HRM 
performs the following two steps simultaneously: PCR amplification and analysis of PCR 
products produced. This technique uses PCR to amplify the DNA regions of interest. HRM 
analysis is then performed on all amplicons to distinguish nucleotide sequence differences 
between samples. During HRM the gDNA amplicons are heated from approximately 50°C to 
95°C. At a particular point during this process the amplicons melt which leads to the 
separation of the two strands, (Figure 2.2). 
sst 

Figure 2.2: Double stranded gDNA process under different temperatures 
(http://en.wikipedia.org/wikilHigh Resolution Melt) 
HRM uses third generation fluorescent dyes that intercalate and bind specifically to double 
stranded gDNA. High levels of fluorescence in gDNA ampl icons are present because of large 
copy numbers of the amplicon , but as the DNA amplicon is subjected to different 
temperatures, the fluorescence levels decrease as the double stranded gDNA separates (figure 
2.3). The HRM machine monitors this process by measuring the fluorescence of the solution. 
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Figure 2.3: A melt curve, showing levels of fluorescence vs temperature 
(http://en.wikipedia.org/wikilHigh Resolution Melt) 
Using this method, two samples from different individuals without a mutation are expected to 
produce exactly the same melt curve shape, but if there is a mutation or any alterations on the 
gDNA amplicon sequence, the temperature at which the gDNA strands melt and separate 
changes, resulting in different melting curves (figure 2.4). 
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Figure 2.4: Two different curves showing normal gDNA and mutated gDNA 
(http://en.wikipedia.org/wikilHigh Resolution Melt) 
A gene has two alleles. When a gene is amplified by peR both alleles are amplified and when 
looking for mutations, three outcomes can be expected: no variations in both alleles (WT), 
both alleles present variations (homozygote) and on Iy one allele shows a variation 
(heterozygote). Each of these outcomes produces a different melting curve (figure 2.5). 
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Figure 2.5: A graph showing three possible results of gene alleles 
(http://en.wikipedia.org/wikilHigh Resolution Melt) 
PCR amplification was performed in a total volume of 25f.l1, which contained SOng of 
gDNA, 1.5 f.lM (1 X) Go Taq ™reaction Buffer that contai ned 1.5 f.lM MgC b, 200f.lM dNTPs, 
20 f.lM of each of forward (F) and reversed (R) primers, I X EvaGreen dye (AnaTech, USA) 
and 0.5 Units (U) of GoTaq polymerase. The cycling conditions used during PCR are 
presented in Table 2.2. 
Table 2.3: peR cycling conditions 
Condition Temperature/ Time Numher of Cycles 
Initial denaturation 90 OC 5 for 10 seconds 1 
Denaturation 95 °C for 5 seconds 
50Annealing temperature* 55 OC for 10 seconds 
Elongation 72 OC for I 0 seconds 
High Resolution Melt 72 ° - 95 OC (0.1 increments) 
*Depends on annealing temperature of the particular amplicon 
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A negative control (~hereby dH20 was used instead of gDNA) was included in all PCR 
experiments. This was done to identify possible contamination that could have interfered with 
the reactants. 
2.4.3 Direct sequencing 
For the mutation screening of amplicon sequences that were larger than 300bps, we 
performed PCR fol1o~ed by direct sequencing of the amplicons. Amplicons were then run on 
an agarose gel to establish whether the PCR reaction worked. Amplicons were then purified 
and sequenced on an ABI Prism '!ll 3100 Genetic Analyzer (Applied Biosystems). 
2.-1.3.1 E'(onuciease treatment 
All the samples that showed variations on dHPLC or HRM analysis were sequenced. Prior to 
the sequencing reactions, samples were treated with Exonuciease J to remove unincorporated 
dideoxy-nucleotide triphosphate (ddNTP) terminators. The following protocol was used per 
sample: 1 U of Exonuclease J (New England Biolabs), 2U Shrimp Alkaline Pho,~phatase 
(Promega) to get rid of single stranded products, 51ll PCR product and dH20 was added to a 
final reaction volume of 20Il!. The reactions were incubated at 3TC for an hour (or overnight 
depending on the manufacturer's instructions) and the enzyme deactivated at 75°C for 15 
minutes. 
2.-1.3.2 Sequencing reactions 
The products were sequenced in both forward (F) and reverse (R) directions to confirm the 
mutations that were observed, The parameters of half reactions were as follows: a minimum 
of 20llM of each F and R primers, 5X Dilution Buffer, 5X Termination Mix, and a quantity 
of gDNA product and dH20 to make up the total volume of 20Il!. The conditions that applied 
in this sequencing are presented in Table 2.3. 
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Table 2.4: Dideoxy-Cycle Sequencing conditions 
Tempertlture ("C) Time Number (~lCycles 
96 5 minutes 1 
96 30 seconds 
25 
50 15 minutes 
60 4 minutes 
2.4.3.3 Sequence ana~vsis 
The sequencing electropherograms from the ABI Prism K 3100 were analyzed using the 
BioEdit programme. The reverse and the forward electropherograms were aligned with the 
wildtype sequences from NCBI and analysed for changes. All rare variants were aligned with 
amino acid sequences of modern species that were obtained from Mutation Taster to 
determine the conservatlOn of the amino acids, they compare the human sequence with the 
modern animals' sequence to look if the amino acid in question is shared among the list of 
modern animals of which if it is shared there the amino acid is predicted to be important and 
it alteration may cause jisease. Splice site prediction by the neural network programme on 
the Berkeley Drosophila Genome Project (BDGP) website 
(www.fruitfly.org/seq_tools/splice.html) was used to predict whether intronic variants could 
be disease-causing or not by altering mRNA splicing. 
2.4.4 Screening of population controls for novel variants 
To determine the frequency of a novel variant in the popUlation, healthy controls with no 
history of cardiomyopathy were screened using either direct sequencing (described in section 
2.4.3) or the HRM method (described in section 2.4.2) in conjunction with direct sequencing. 
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2.4.5 Bioinformatics: prediction tools 
The pathogenicity of all non-synonymous rare novel variants was assessed using the 
Polyphen-2. PolyPhen predicts the effect of nsSNPs by combining a number of properties 
relating to the structure and function of the encoded protein. The user can provide a UniProt 
ID or copy and paste the query sequence in FASTA format. The substitution (one per run) is 
also required. (http://g.;netics.bwh.harvard.edu), SIFT (Sorting IntolerantFrom Tolerant) is a 
program that predicts whether an amino acid substitution affects protein function so that users 
can prioritize substitutions for further study. We have shown that SIFT can distinguish 
between functionally neutral and deleterious amino acid changes in mutagenesis studies and 
on human polymorphisms. To predict whether an amino acid substitution in a protein will 
affect protein function, SIFT' considers the position at which the change occurred and the type 
of ammo acid change (http://sift.bii.a-star.edll.sg/), and MlitationTaster 
(http://www.mutationtaster.org/) prediction programmes. Only those variants predicted to be 
disease-causing in a protein of interest by at least two of the prediction tools were considered 
for further analysis. The pathogenicity of synonymous rare variants was assessed using the 
RNAfoid webserver (hltp:llrna.tbi.univie.ac.at/) and MutationTaster tool. MutationTaster is a 
fast web-based application to evaluate DNA sequence variants using information from 
various sources combined and evaluated in a naive Bayes classifier. A prediction is given as 
either disease-causing C)r polymorphism along with a P value indicating the security of the 
prediction (with 1 being most secure). A breakdown of all of the components that contribute 
to the prediction is also provided (http://www.mutationtaster.org/). In the case of non-coding 
variants. the Berkeley splice site prediction by neural network tool 
(hup://www.fruitfly.org/seqtools/splice.html) and alternate splice site predictor 
(http://wangcomputing.com/assp/index.html) were used to predict splice site mutations. 
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MutationTaster is a fast web~based application to evaluate DNA sequence variants using 
information from various sources combined and evaluated in a naive Bayes classifier. A 
prediction is given as either disease~causing or polymorphism along with a P value indicating 
the security of the prediction (with I being most secure). A breakdown of all of the 
components that contribute to the prediction is also provided(http://www.mutationtaster.org/). 
2.5 FOUNDER EFFE CTS 
2.5.1 Haplotyping 
Three single tandem r~peats (STR) were used in this experiment: PKP2_3'_CAI marker at 
position 2415474 to 241529. a published D 12S 1692 marker at position 7275538~ 727786 and 
PKP2_5' TGlmarkeI at position 825316 to 825348, which were selected from the genomic 
sequence of PKP2. Primers for the D 12S 1692 marker were published in NCBI (rs 11341966). 
Table 2.4 illustrates primer information. These primers were selected to span 5'. intragenic 
and 3' regions of P KP.: (Figure 2.6). 
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Figure 2.6: Illustration of two manually selected STR markers (PAP2_3'_CA1; PAP2_S'_TGl) 
flanking PKP2; one reponed intragenic marker (D I 2S I 692) and variants that were detected in family probands 
(red boxes) 
Table 2.5: Primer sequences for PKP2 microsatellite markers 
!\Iarker Primer sequence .\nnealing Amplicon size (bps) 
temperature 
PKP2_3'_CAI F GAGGAACAGGTGGGCTGAG 

R_G,\AACGAACCCCAGTAATGTC TC 

21Sbps55°C 
D12S1692 F _C1TTGATTCCATACCCTCCT 

R G(,AGCAATTTCAGACTTCTC 

249bpsS2°C 
PKP2_5'_TGI F_T(,GGTCTGTA TGTGTTTGCT 
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R CATACACTCTCAAATAGAAATAGG I 
51 
104bps 
i 
2.5.2 Variants and SNl's used as markers 
Two markers were typed for haplotype construction. in addition to the 5'. intragenic and 3' 
STR markers. These two markers were the common PKP2 SNP rs1046116 (c.T1097C, 
p.L366P) in exon 4 aM the PKP2 InOel (A 733fsX740) mutation in exon 11. 
2.5.3 Genotyping of the markers 
STR markers were genotyped in all four ARVC families (N=13) and 50 ethnically matched 
controls using PKP2 laoeJed (F AMI HEX florescence) primers (Appendix 2: Table 5). 
2.5.4 Haplotype and ·a~.sumed' haplotype construction 
Construction of the most likely haplotype was designed with reference to the gene and STR 
marker order on chromJsome 12, in the context of the family. The most probable haplotypes 
were constructed manu lily based on pedigree data and marker positions. In the two cases for 
which only the probanc' was available for genotyping. an "assumed haplotype", based on the 
haplotype identified by family mapping, was generated (Moolman-Smook, Oe Lange et at. 
1999). 
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2.6 CIS-EFFECT ON GENE EXPRESSION 
Tests for the cis-effed of SNPs on gene expression were performed in two different 
experiments: total gene expression (section 2.6.6) and allelic expression imbalance (section 
2.6.7). 
2.6.1 Cohorts 
For this study periphera blood RNA and DNA were taken from 192 North East and 307 
South African healthy p')pulation controls. 
2.6.2 RNA sampling 
The blood (2.5ml) was collected in PAXgene® Blood R7'lA (PreAnalytiX) tubes for RNA 
extraction. 
2.6.2.1 RNA handling procedures 
RNA tasks were performed in the Microflow Laminar workstation using dedicated equipment 
designed for said tasks. Equipment and working surfaces were treated with RNase away 
(Sigma- Aldrich. UK) or 100% alcohol prior to RNA extraction to eliminate the possibility of 
contamination. Only designated pipettes and sterile RNase-free labware were used in RNA 
processing. 
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2.6.2.2 RNA sample collection, extraction and quality control 
For the South African control samples, peripheral blood was collected in PAXgene RNA 
tubes and was stored al -SO°e. The blood samples were placed at room temperature for 2-3 
hours before extraction. All the extractions were perfom1ed according to the manufacturer's 
instructions. All sampks were eluted into a total of volume of SOIlI distilled water (dH20) 
and were stored at -SO°C after extraction. RNA concentrations were measured using the 
NanoDrop ND-3000 spectrophotometer (NanoDrop Technologies, USA). 
All RNA samples were DNase I treated using RQ I RNase- free DNase (Promega, USA) prior 
to reverse transcription following the manufacturer's standard protocol to eliminate genomic 
DNA contamination. Fragment sizes and quality of RNA and cDNA were tested for selected 
samples using the RNA 6000 LapChip Kit (Agilent, USA) and the Agilent 2100 Bioanalyzer 
following manufacturer's instructions. 
2.6.2.3 Reverse transcription 
A total amount of 50ng to 21lg RNA was reverse-transcribed using the SuperScript III First-
Strand Synthesis System for RT-PCR (Invitrogen, USA) and Omniscript III reverse 
transcription kit (Qiage 1, Germany). To reverse-transcribe RNA, the manufacturer's protocol 
was followed and all s.lmples were eluted in a total volume of 20111 dH 20. All cDNA was 
stored at -SOlle. The dilution of cDNA to working concentrations was performed assuming a 
I: I ratio of RNA to revl~rse-transcribed cDNA. 
2.6.3 Genomic DNA sampling 
Blood (S.5ml) was collected in PAXgene® DNA tubes for gDNA (PreAnalytiX, BD 
company). 
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2.6.3.1 gDNA handling 
Genomic DNA tasks \\ere performed in the Microflow Laminar workstation using dedicated 
equipment designed for said tasks. Equipment and working surfaces were treated with 100% 
alcohol prior to gDNA extraction to eliminate the possibility of contamination. Only 
designated pipettes and sterile DNase-free labware were used in DNA processing. 
2.6.3.2. DNA sample collection. extraction and quality control 
Please refer to section 2.2 above 
2.6.4 Selection of single nucleotide polymorphisms for gene expression investigation 
Three SNPs, in three di tTerent desmosomaJ genes, were selected for this study: rs 1 046116 in 
PKP2. rs79241 126 in DSG2 and rs868333 in DSC2. These SNPs all had a minor allele 
frequency greater than 5% in the healthy population controls. 
2.6.4.1 Plakophilin-2 (PKP2); rs1046116 SNP 
The rsl046116 SNP in PKP2 was found in both ARVC and DCM probands. The rs1046116 
SNP was identified in four ARVC probands and was segregating with a founder mutation in 
the coding region of P}'~P2 (chapter 4). The rsl046116 SNP had a minor allelic frequency 
(MAF) that was greate' than 0.05, a minimum criterion for inclusion of a SNP in the 
experiments on allelic expression imbalance (AE!) and total gene expression. 
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2.6.-1.2 Desmoglein-2 (DSG2); rs79241126 SNP 
The rs7924 I 126 SNP \vas detected in the coding region of exon 14 of DSG2 and was found 
only in ARVC index cases and population controls. It was also reported in NCBI from Utah 
residents with Northern and Western European ancestry from the CEPH collection (CEU) 
where the minor allelic frequency was 0.05 while there was no available information on the 
HapMap-Y oruba (YRI: cohort. 
2.6.4.3 Desmocollin-2 rDSC2); rs868333 SNP 
The rs868333 SNP wa., detected in only one ARVC index case in exon I of DSC2 but was 
very common in our population controls and was also published in the ARVC database 
(www.arvcdatabase.inb) and NCBI dbSNP (http://www.ncbi.nlm.nih.gov/SNP/). The minor 
allele frequency for thi.; SNP was 0.11 in the CEPH families and 0.46 in a YRI low coverage 
panel. The MAF for both ethnicities met the requirement for the SNP inclusion in the 
experiments on allelic expression imbalance and total gene expression. 
2.6.5 Primer design for gene expression in peripheral blood 
A set of primers was designed, using Primer3 (v.0.4.0) (ww\v.primerdesign.co.uk), in each 
gene in such a way that a forward primer will be situated inside one ex on and a reverse 
primer inside the next ex on using a cDNA sequence from Ensembl.org (Table 2.5). 
Specificity of primers was investigated by quantitative PCR (qPCR). The primers were 
tested in both cDNA and gDNA products. gDNA contamination in cDNA would be easily 
detected as we know that cDNA has no intronic regions and should not produce an amplicon 
with the intronic primers. The successful primers were used to amplify both cDNA and 
gDNA of all genes of interest using the amplification method and visualized in agarose gel. 
Table 2.6: Desmosomal gene expression primer information 
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Primer name Primer seq. Annealing [:\on gD'.\ cD' \ 
temp. (bps) (bps) 
1093 1403I DSC2 F -primer I TCCAACACTGAGAACCAAGAAA : 60.0 
4DSC2 R-primer I AGC ATCGAACAAGGAATTGG I i 60.0 
267PKP2 F-primer ATTrTGTTGGAGGCCGTTC 5 643I 
I !6 i I59.0GCCTGCTTTCTTGGTGGTI PKP2 R-primer J I 
I I I 
I58.0 171I DSG2 F-primer I CTG0AAAAGGGATTACAGAGC 
: 305 I 
TGC'0T AGCTCT AAGGGTTTC 58 0 iI DSG2 R-primer 
1 . I: 
i 
I J 
2.6.6 Total gene expression studies using peripheral blood 
gDNA was used to genotype the controls for the associated SNPs of interest as described 
below. Total gene expression in genes of interest was measured by quantitative real time PCR 
(qRT-PCR) using App,ied Biosystem TaqMan gene expression assays. The reactions were 
performed in replicates of four on an ABI PRISM 7000l·IT sequence detection system. The 
expression was measured relative to the housekeeping genes (beta actin (A CTB) , 
glyceraldehyde-3-phosrhate dehydrogenase (GAPDH) and RNA, 18S ribosomal 
(RN18S1». For each ~:ene, the Delta Ct values for each control were plotted against each 
SNP genotype and linear regression was used to determine if gene expression (relative to 
genotypes) varied significantly from null. 
2.6.6.1 SNP geno~vpe d/~'Crimination 
Genotyping of the S}';Ps of interest was carried out by Applied Biosystem TaqMan 
genotyping assays. 
TaqMan SNP genotyping was carried out in a Microflow Laminar flow workstation with pre-
PCR pipettes to prevent any possibility of contamination. The genotyping was performed 
using predesigned Taql\1an SNP Genotyping Assays (Applied Biosystems, USA). In PCR, 
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20-25ng of DNA template was used in a total volume of 5JlI reaction in 384-well optical 
reaction plates. The peR master mix for each sample was made of 2.5JlI PCR Genotyping 
Master Mix (Applied Biosystems, USA), 0.125JlI of 40xAssay Mix (Applied Biosystems, 
USA), 1.375JlI of nuclease-free water, and I JlI of DNA template. PCR conditions used during 
Taqman SNP genotyp ng are summarized in Table 2.6. Non-template controls were included 
for quality control to exclude any possible contamination. 
Data were analysed using the allelic discrimination algorithms In SDS Software v2.3 
(Applied Biosystems, USA) according to the manufacturer's instructions. The data were also 
used to calculate both genotype and allelic frequencies in the South African cohort and to 
compare their frequencies with dbSNP frequencies in NCBI in order to determine if the 
frequencies identified were similar to those of other Africans. 
Table 2.7: PCR cycling conditions for TaqMan SNP genotyping reactions 
Temperature (C( ') Tinlc .\"wnher of (rc!e\ 
95 10 minutes I 
92 15 seconds 
4060 I minute 
2.6.6.2 Quantitative real-time PCR 
Quantitative Real-time PCR reactions were done using TaqMan gene expression probe assays 
and reagents from Applied Biosystems (USA) and were performed using the 7900HT Real­
time PCR System (Applied Biosystems, USA). Gene expression PCR was performed using 
5.0 ng/JlI of cDNA in a 15JlI reaction volume and reactions were performed in a 384 well 
reaction plate. Multipl\!x reaction mix was used to accommodate a FAM-labelled target gene 
assay (PKP2) and VIC-labelled control gene assay (ACTB. GAPDH and RN18S1) in the same 
reaction. TaqMan as~;ays are validated by the manufacturer to have close to 100% 
amplification efficiency. PCR mix for each sample was made of 7.5Jl\ TaqMan Gene 
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expression master mil- (Applied Biosystems, USA), 0.75j..l1 of 20x target gene primer/probe 
mix (Applied Biosyscems, USA), 0.75 j..l I 20x control gene primer/probe mix (Applied 
Biosystems, USA); 1.0j..l1 of nuclease-free water, 5.0j..l1 of cDNA sample. PCR conditions 
used for gene expression are summarized in Table 2.7. Four replicates of each sample were 
performed. Non-template controls were included for quality control. Relative total gene 
expression was analysed using the comparative cycle threshold (0) method using SDS 
Software v2.3 and RQ Manager 1.2 software (Applied Biosystems, USA) according to the 
manufacturer's instructions. Ct values were normalised to the mean 0 value of the reference 
gene. Normalised 0 v,dues were used in all analyses (O=mean= target gene Ct value - mean 
reference gene value). 
Ta ble 2.8: Total gene expression PCR conditions 
Temperature ('t OJ Time Xumher oj" ()de\ 
50 2 minutes 1 
95 10 minutes 1 
95 15 seconds 
45 
60 1 minute 
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The association betwten total gene expression and the PKP2 SNP, rs 1 046116, was tested 
using a linear regression of the log transformed expression normalized values on the 
genotypes of the same PKP2 SNP. The analysis was performed using Rand SigmaPlot vI 1.0 
where the effect size of the expression is given as the slope of the regression analysis. The 
association between total gene expression and SNP genotypes was tested using a linear 
regression of the log transformed normalized expression values on the genotypes of the same 
SNP. 
2.6.7 Allelic gene expression imbalance 
2.6.7.1 SNP genotyping discrimination 
Genotyping of 307 ~outh African (SA) population controls were performed to identify 
heterozygote samples using real-time peR as described above. 
2.6.7.2 Artificial Heteloz:vgous 
Artificial heterozygotfs were also made with genomic DNA from homozygotes of both the 
major allele and the minor allele to test the reliability of the Sequenom assays. An artificial 
herterozygote is a heterozygote sample produced by mixing two samples at certain ratios, one 
homozygous sample DNA from wild type and one sample from homozygous with minor 
allele which contains the SNP of interest. The gDNA homozygotes were mixed in the 
following ratios (major allele: minor allele): 8: I; 4: I; 2: 1; I: I; 1 :2; 1:4 and 1 :8. Finally the 
ratio mixtures were diluted to make a total concentration of 25ng/ul. The assay was 
performed on the arti :icial heterozygote to demonstrate that there is a reliable correlation 
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between the known ratio of the two alleles and the ratio of the alleles detected by the 
Sequenom assay. 
2.6.7.3 Quant(fication '~lallelic expression using Sequenom pla{form 
In both mixed gDNA (artificial heterozygotes) and eDNA samples, a concentration of 
25ng/ul for each sample of our SA cohort was sent to the High Throughput Array Facility 
(High throughput gen'Jmics) at the Welcome Trust Centre for Human Genetics (Oxford 
(UK» to quantify the samples using the Sequenom platform. Quantification of the allelic 
expression ratio was done by primer extension and MALDI-TOF mass spectrometry. 
Amplification of gDNA with purification of products was performed in replicates of four. 
2.6. 7 . .J. Allelic expression ana~vsis 
Spectra from the Sequenom assay were manually reviewed. All poor quality spectra with 
high cluster background were excluded. Allelic ratios were calculated as the ratios of the area 
under the peak repre~enting allele I to the area under the peak representing allele 2. 
Measurements were performed in four replicates. Since artificial heterozygote (gDNA) 
samples were taken in a small number of genomic samples to provide normalization, average 
allelic ratio for all genomic DNA samples were selected to determine the normalization factor 
and then used to normalize each of the cDNA ratios using the following formula: 
Normalized allelic ratio = Average ratio of cONAl Average allelic ratio of gDNA 
2.7 EXOME SEQUEl\CING 
The principle behind exome sequencing is to sequence the coding genomic regions of the 
whole genome and align them with the reference sequence. The process involves: 1) 
Preparing the genomic DNA library preparation (section 2.7.1), 2) Cluster Generation (CG) 
- to clonally amplify the library to several million copies (section 2.7.2), and 3) Sequencing 
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by Synthesis (SBS) - this is forward and reverse sequencing of the c10nally amplified library 
clusters (section 2.7.3). 
2.7.1 Sample Library preparation 
Exome sequencing samples were prepared using Illumina' s Paired End Sample Preparation 
Kit (PE-I 02-1 001, I1lumina) and 50Mb SureSelect Human All Exon Capture kit (Agilent 
Technologies) and following instructions of the IlIumina Paired End Sample Preparation 
Guide (Part 1005063, RevD, Feb201 0, 1IIumina). 
2.7.1.1 gDNA quant(fication andfragmentation 
The concentrations for all gDNA samples were obtained using a Qubit Fluorometer and 
dsDNA Broad Range Assay kit following kit instructions (Invitrogen, Life Technologies). 
Then 61lg of high quality gDNA was diluted with 1 X Low TE Buffer in 1.5ml LoBind tube to 
make a total volume of 100111. The 100111 gDNA dilution was transferred to a Covaris tube 
and all air bubbles were removed at the bottom of each tube. This tube was then loaded onto 
a Covaris S2 machine, (Covaris) and the gDNA was fragmented with shear settings as 
follows: duty cycle ,.'as 20%; intensity was 4; cycles per bust were 200; time was 118 
seconds; set mode wa·.; put in frequency sweeping and temperature was at 4°C. The step was 
repeated to ensure complete fragmentation. Then the fragmented gDNA was transferred back 
to l.5ml LoBind tub~s. To purify the fragmented gDNA, 500111 PB buffer was added to 
fragmented gDNA in the 1.5ml Lobind tube and mixed by pipette. A total of 600111 was 
transferred to a QIAqdck peR column and centrifuged for 1 minute at 13000 rpm. The flow-
through was discarded and 750111 of PE buffer was added to wash the column, centrifuged 
for I minute and the flow-through was discarded and centrifuged for another I minute to 
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completely remove residual PE buffer. Then the QlAquick columns were placed in 1.5ml 
LoBind tubes and left open for 5 minutes at room temperature to allow evaporation of any 
residual ethanol. The gDNA was eluted into 30111 of Nuclease-free water and the elution step 
was repeated twice to make a total of 60111. Using a Savant DNA 120 SpeedVac Concentrator 
(Thermo Scientific), DNA samples were concentrated to 30111 and fragment sizes were 
checked using a 2100 Bioanalyzer and DNA 1000 lab chip (Agilent Technologies), to see if 
sizes were in the correct range of 150 to 200 base pairs. 
2.7.1.2 DNA Librm~v preparations 
2.7.1.2.1 End Repair 
All reagents were supplied in the IIIumina Paired End Sample Preparation kit (PE-I 02-1 00 I. 
1IIumina). The gDNA fcagments achieved by the Covaris shearing method results in 3' and 5' 
overhangs and blunt ends. The purpose of End Repair is to convert all the overhanging 
fragments to blunt end~. For this, the following reagents were added to each sample: 45111 of 
water; 30111 of gDNA sample; 10111 of T 4 DNA Ligase Buffer with 10mM ATP; 4\l1 10mM 
dNTP Mix; 5111 of T4 DNA polymerase; I III Klenow Enzyme and 5111 of PNK. They were 
pipette mixed and incubated in a thermal cycler (BioRad tetrad) for 45 minutes at 20°e. Then 
the 100111 End repair nix was purified. The purification step was carried out using the 
QIAquick PCR kit and was performed as mentioned above and the eluate was concentrated to 
32 III using the SpeedVac (Thermo Scientific). 
2.7.1.2.2 Adenyiation 0/3 'ends 
The adenylation step was performed. A single' A' nucleotide was added to the 3' ends of the 
blunt fragments to prevent them from ligating to one another during the adapter ligation 
reaction. A correspond ng single 'r nucleotide on the 3' end of the adapter provides a 
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complementary overhalg for ligating the adapter to the fragment. The following reagents 
were added in each sarr pie (sample volume 32ul): 5111 of Klenow buffer; 10111 of I mM dA TP 
and 3111 of Klenow Ex,o with a total of 50111. The reactions were mixed by pipette and 
incubated for 30 minutes at 37°C. Reactions were then purified in Qiagen MinElute PCR 
Purification columns (Qiagen) per instructions. The fragments were eluted in nuclease-free 
water and concentrated (with SpeedVac) to 10111 before proceeding to Adapter ligation. 
2.7.1.2.3 Paired End adapter ligation 
Adapters were ligated to all adenylated fragments by adding the following reagents to the 
10111 gDNA: 25111 2X DNA ligase Buffer; 10111 PE adapter Oligo Mix and 5111 DNA Ligase 
and this made a total volume of 50111. The mixture was mixed by pipette and incubated on a 
thermal cycler for IS minutes at 20°e. 
Following the incubation, the ligation reactions were purified with Agencourt AMPure XP 
beads (Beckman Coulter). The AMPure XP beads were allowed to remain at room 
temperature for at least 30 minutes and the reagent was mixed. 90111 of the homogenous 
beads were added to the ligation reaction and mixed well by pipette. The mixture was then 
incubated for 10 minutes at room temperature. The reactions were performed in a PCR plate. 
The plate was then plat..:ed in a magnetic stand for approximately 3 to 5 minutes in order to 
separate the beads. The clear solution (supernatant) was discarded from the wells of the 
plates. Leaving the PC R plate on the magnetic stand, the beads with the ligated products 
bound to them were washed. This was performed by adding 200111 of 70% ethanol over the 
surface of the beads and then removing the ethanol. The wash step was repeated and the plate 
was left for a few minutes at room temperature until residual ethanol had evaporated. 30111 
Nuclease-free water was then added to the beads after removing the plate from the magnetic 
stand to bring the beads back into solution. This resulted in the detachment of the ligated 
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fragments from the beads back into the water. To aid this, the mixture was left at room 
temperature for 5 minJtes and the plate was then placed back on the magnetic stand. This 
time the supernatant \Vas transferred to a clean 1.5ml Lobind tube. This elution step was 
repeated and the volurre brought down to 30~.d with the SpeedVac. 
2.7.1.3 peR enrichment of Paired End adapter ligated DNA fragments 
2.7.1.3.1 Polymerase chain reaction (peR) 
The next step was to perform a peR with two primers supplied in the IIlumina prep kit (PE-
102-100 I, I1lumina). This was done to selectively enrich fragments with adapters on both 
ends and to amplify the amount of DNA in the library. This peR step performed four key 
functions: 1) by using the two primers, additional sequences are added to the ends of the 
adapters so that it aids the hybridization of the fragments to the oligonucleotides of the flow 
cell surface for cluster generation, 2) enriches for fragments with adapters on both ends as 
other species such as fragments with an adapter on only one end would not work for cluster 
generation, 3) enriches fragments to eliminate adapter dimers. and 4) amplifies the amount of 
DNA. The peR mixtUi'e was as follows: 12111 library from previous step; II III Nuclease free 
water; IIlI peR primer PE 2.0; IIlI peR primer PE 1.0 and 25111 2X Phusion Master Mix. 
The reactions were mi(ed by pipette and placed in a thermal cycler. The reaction conditions 
are listed in Table 2 8. After amplification, the peR products were purified using the 
AMPure XP beads as detailed previously and the volume brought down to 30111 with the 
SpeedVac. 
2.7.1.3.2 Purification ufthe peR. 
Following peR clean JP. fragment sizes were checked using a 2100 Bioanalyzer and DNA 
1000 lab chip (Agilem Technologies), in order to see if sizes had shifted from those at the 
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start as additional base) (adapters) have been added and for accurate quantification as 500ng 
is required for the next step, exome enrichment. 
Table 2,9: peR cycling conditions 
Exome2.7.1.4 
., emperature 
(t 'J 
Time 
.\ /1mher o(()de, 
98 30 seconds 
98 
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40 seconds 
30 seconds 4 
72 30 seconds 
72 5 minutes 
Enrichment: The Hybridization step 
A 50Mb SureSelect Human All Exon Capture kit (Agilent Technologies) was used. The kit 
contained all the components required to set up the hybridization and to clean up the reaction 
after hybridization. Th( procedure has 3 distinct parts (labelled I to 3) and all parts were 
combined to give a mixture of prepped library ( collection of DNA fragments prepared for 
exome sequencing), bailS, and PE blockers which was then incubated on a thermal cycler for 
24 hours at 65°C. Ail detailed instructions are contained in the SureSelect guide that 
accompanies the kit. 
2.7.1.4.1 ParI 1: prep(JrIl1iono(DNA capturep/ate 
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The first R1\'Aase bloc k was diluted to make a ratio of I: I with Nuclease-free water and 
placed on ice. Jill ofNJclease-free water was added to a well ofa 96 well PCR plate; 5 III of 
the bait was added to i:. Then Jill RNAase block was added to that whilst keeping the plate 
on an ice block. The resulting 7111 of wateribaitlR\JAse block mixture was mixed using a 
pipette and the wells c.)vered with a cap and the plate, labelled as the "Capture Plate"; this 
was left aside in the ice block. 
2.7.1.-1.2 Part 2: Hybridization buffer preparation 
For every reaction that was performed, the following butTers from the SureSelect kit were 
added in 1.5 ml Eppendorf tubes: 25111 of SureSelect Hyb # I; 1111 of SureSelect Hyb #2; 10 
III of SureSelect Hyb #3 and 10111 of SureSelect Hyb #4. They were mixed by vortexing and 
spun down by centrifugation. To avoid precipitation. the buffer mixture was kept at 65°C 
unti I ready to use. 
2.7.1.-1.3 Part 3: Prepped library 
A 'prepped' library is a collection of DNA fragments prepared for the experiment.The library 
was quantified in the last step. From that, the volume of each library was adjusted, using the 
SpeedVac, to contain SOOng in 3.4111 of 1\'uclease-free water. This was done in a 1.5ml 
Lobind tube. To this volume, 2.5111 of block # I, 2.5111 of block # 2 and 0.6111 of block # 3 
(PE) were added to give a total volume of 9111. They were mixed by pipetting and left on ice 
for 10 minutes. 
After the 10 minutes, the library was transferred to a PCR plate, not on ice, and in a separate 
well, 40111 of hybridization buffer was added. The plate was then put in a thermal cycler and 
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following program wa~ used: 95°C for 5 minutes and a hold at 65°C. This was to denature the 
libraries. After the plcte was at 65°C for 2 minutes, the ''Capture plate" was removed from 
the ice block and put in another block of the thermal cycler to run at 65°C. When both plates 
were at 65°C for at lea)t 5 minutes, the 9111 of prepped library was added to the capture plate 
well, and 13111 of buffer added to a final volume of hybridization mixture of 29111. This was 
then left at 65°C for 24 hours. 
After the 24 hours, there were steps to remove fragments that hadn't hybridized to the baits, 
i.e. non-exonic regions; RNA baits were then digested from the library fragments which were 
from the exon regions. Full details are in the guide from Agilent Technologies accompanying 
the exome kit. 
2.7.1.5 Post-hybridizalion ampi{fication 
Next, post-hybridizatitm amplification was performed to amplify the library samples that 
have been through the exome enrichment step. The reaction setup was the same as before: 
12111 enriched library; 11 III Nuclease-free water; I III PCR primer PE 2.0; I III PCR primer PE 
1.0 and 2511' 2X Phusion Mix were added. They were mixed by pipetting and the reaction 
mixture was placed in a thermal cycler as before (Table 2.8) but the number of cycles was 
increased (Table 2.9). Following amplification, the libraries were cleaned up with the 
AMPure XP beads as described previously and the eluent was concentrated to 30111. 
Table 2.10: Post-hybridization cycling conditions 
Temperature Time .\lIll1heroj()de\ 
(O( 'j 
98 30econds 
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98 40 seconds 
65 30 seconds II 
72 30 seconds 
72 5 minutes 
2.7.1.6 Paired End librm:v quantification 
Finally, the libraries were accurately quantified and profiles checked before being sequenced 
and this was done using the 2100 Bioanalyzer and High Sensitivity lab chips (Agilent 
Technologies). Samp1e~ were ran in duplicate and an average of the concentrations and 
library sizes taken to calculate the amount in nM which is critical for sequencing and optimal 
cluster generation 
2.7.2 Cluster Generatioll 
The cluster generation and sequencing was performed by a technician at the Institute of 
Genetic Medicine, Newcastle University, UK, and involved the amplification of DNA 
libraries in an Iliumina f:'low Cell. The flow cell is made up of eight lanes and each lane has 
a dense lawn of oligom,cleotides attached to the inside surface. These are complimentary to 
the Paired end adapter:, flanking the gDNA libraries. The first step was to denature the 
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libraries to single-stranded fragments at a set concentration (2nM) usmg I N sodium 
hydroxide and then loading 12pM of the denatured library in each lane so that the template 
hybridized to the flow.::ell via the lawn of oligonucleotides. Then unlabeled nucleotides and 
enzyme were added to initiate solid-phase amplification which is termed "Bridge peR". The 
enzyme incorporates llucleotides to build double-stranded DNA on the flow cell. Once 
completed and at the next denaturation step, the single stranded fragment loops over and as it 
has a complimentary sequence, it binds to another of the oligonucleotides bound on the flow 
cell surface, i.e. a "bridge" is formed, and amplification is repeated. In this way fragments 
were clonally amplified and several million clusters per lane were generated. Finally, cluster 
generation was completed. The reverse strands were cleaved and washed away. Ends were 
blocked and the sequencing primer was hybridized to the DNA template and the flow cell 
was then ready to load ~m the GAllx for sequencing. 
2.7.3 Sequencing by Synthesis (SBS) 
Following cluster generation, the flow cell was sequenced on the IIIumina GAllx sequencer 
with a 75 cycle Paired End recipe. This included 75 cycles of sequencing in the forward 
direction (termed Read I) followed by 75 cycles in the reverse direction (termed Read 2). 
On the Genome Analy~,er, hundreds of millions of clusters are sequenced simultaneously. The 
DNA templates are sequenced base by base, in parallel, using four fluorescently-Iabelled 
reversibly terminated ·lucleotides. All four bases compete with each other to bind to the 
template. This natural competition ensures the highest accuracy. After each round of 
synthesis, the clusters Hre excited by a laser and show a colour that identifies the newly added 
base. The fluorescent label and blocking group are then removed, allowing for the addition of 
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the next base. This pr.)prietary chemistry reads the single base added in each cycle, thus 
enabling accurate sequencing through difficult regions such as homo polymers and repetitive 
sequences. 
After sequencing 75 cycles in the forward direction the clusters were processed for reverse 
strand sequencing in situ using the Paired End Module. This was exactly the same as Cluster 
Generation except that afterwards the forward strands were cleaved and washed away, ends 
blocked, reverse sequelcing primer added and 75 cycles of sequencing performed. In this 
way 55 to 82 million reads per lane were generated. 
2.8 Bioinformatic analysis 
2.8.1. Alignment and v('xiant calling 
Raw data was analyzed by Professor Bernard Keavney's Bioinformatics Unit at the Institute 
of Human Genetics (Centre for Life) at the University of Newcastle upon Tyne, (UK) where I 
spent nearly a year working on this project under his supervision. Novoalign 
(http://www.novocraft.com) was used to align the sequence reads to the UCSC human 
reference genome (http://genome.ucsc.edu/; hgl9) and SAMtooJs (Li, Handsaker et al. 2009) 
was used to call the variants. 
2.8.2 Variant filtering 
Initially all off-target variants were removed and only those shared by two affected 
individuals were selected for further downstream analysis. Following this, all SNPs within 
the dbSNP 135 databcse were removed. Finally, only those variants with a total base 
coverage 2: I Ox and a quality score> 10 were selected. 
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Variant pathogenicity \Vas assessed using the \!1utationTaster, Polyphen-2 and Sift prediction 
programs as mentioned in section 2.4.5. 
The base coverage, quality scores and dbSNP135 database were decreased in order to identify 
variants present in gems known to cause/influence cardiomyopathy. 
2.8.3. Public Genome browsers 
uese (http://genome.ucsc.edu/) and Ensembl (http://www.ensembl.org) genome browser 
programs were used t(> map amino acids affected by the variants, positions of the affected 
amino acids and to retreve the cDNA sequences of the specific genes of interest. 
2.8.4 Public databases 
1000 Genomes (bttp://www.l OOOgenomes.org/), Exome variant sever (EVS) 
(http://evs.gs.washington.edu), dbSNP (www.ncbi.nlm.nih.gov/SNP/) and ARve databases 
(www.arvcdatabase.info) were used to identify whether the variant had been previously 
identified and to obtain allelic frequency information. 
2.8.5 Validation of potentially disease causing mutations 
All genes harbouring identified mutations were annotated and a set of primers was designed 
to amplify the product containing the variant (Table 2.10). Genomic DNA was amplified and 
peR products were vi~ualized on an agarose gel. The frequency of variants was investigated 
in population controls and was perfonned using HR\!1 followed by sequencing. 
Table 2.11: Primer information of three genes with variants share by affected 
individuals. 
Gene Primer sequence Amplicon size 'felting temp. 
72 
(bp) ("C) 
55248PARrA F-CAGGAGGAGGGAATGAAC 
R-CGCTCCTGATTTCTTCTT AC 
221 61HMGXB3 F-CAGGC A 1GGCAGAGCAGT 
R-AGTGGG(iAGGTCTGGTGAG 
300 57UBR-I F-GCAAGAGCAGGAAGAATTTG 
F-CTGGGCCTCTGGAGTTACT A 
2.8.6 Investigation of genes harbouring possible mutations in heart tissue 
Primers specific to cDNA were designed Crable 2.11) as mentioned in the investigation of 
gene expression in peripheral blood (see section 2.7.4). PCR products were visualized in an 
agarose geL 
Table 2.12: primer information for gene expression in heart tissue 
Gene Primer sequence .\mplicon size 
(bp) 
i\lelting temp. 
("C) 
PARVA F-CACTCATCACTTTCGTGAAC 170 54 
R-CTTCTGTTCAAAGCTGTCC 
HMGXB3 F-AGGTAACTGTCGTGATGGAG 300 SO 
Chapter 3 

Prevalence of desmusomal gene mutations in Arrhythmogenic Right Ventricular 

Ca,·diomyopathy and Dilated Cardiomyopathy 

3.1 INTRODUCTION 
The first report of desmo:;omal gene mutations as a cause of dilated cardiomyopathy (DCM) 
in addition to arrhythmngenic right right ventricular cardiomyopathy (ARVC) was the 
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discovery of recessive desmoplakin mutations as a cause of the Carvajal syndrome (Norgett, 
Hatsell et al. 2000). Carvajal syndrome is characterised by palmoplantar keratoderma with 
left ventricular cardiomyopathy and woolly hair. Subsequently, Elliot et al. identified 
autosomal dominant d,!smosomal gene mutations as a cause of OCM in 5% of English 
patients (Elliott, O'Mahony et al. 2010). These observations suggested that desmosomal gene 
mutations cause both ARVC and OCM outside Africa. However, little is known about the 
frequency of desmosomal gene mutations in Africans with ARVC and OCM (Sliwa and 
Mayosi 2013, Sliwa and Mayosi 2013). 
Prior to my work, there were no studies of desmosomal gene mutations in African patients 
with cardiomyopathy. :vty initial work included genetic screening of the first 36 participants 
in the ARVC Registry of South Africa for mutations in the plakophylin-2 (PKP2) gene 
(Watkins, Hendricks et al. 2009). In this study we demonstrated that PKP2 mutations are 
found in a quarter of ,A.frican patients with ARVC. In this work, r have extended the genetic 
screening of desmosomal gene mutations in cardiomyopathy in three significant ways. First, I 
screened an additional 29 ARVC patients for mutations in PKP2. Second, I screened 65 
ARVC patients enrolled in the ARVC registry of South Africa for mutations in three 
additional desmosomal genes: desmocollin 2 (DSC2), desmoglein 2 (DSG2), and plakoglobin 
(JUP). Finally, r extended the desmosomal genetic screening to 112 cases of OeM based on 
the findings of Ell iot e l af (Ell iott, O'Mahony et al. 20 I 0) in order to delineate the prevalence 
of desmosomal gene mutations in Africans with OCM. 
Hypothesis 
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We hypothesized that in our cohort of South Africans with cardiomyopathies, both ARVC 
and OCM are caused b) desmosomal gene mutations, and that the same mutation may result 
in either in an ARVC or OCM phenotype (i.e., phenotypic heterogeneity). 
3.2 STUDY AIM 
The main aims of this chapter were to determine: 
1. The prevalence of desmosomal gene mutations in South Africans with ARVC as 
compared with DCM; 
2. Whether participants with ARVC and OCM share similar mutations, and thus lending 
support to the hypothesis of phenotypic heterogeneity of desmosomal gene 
mutations; 
3.3 METHODS 
DNA samples were available for 177 index cases with cardiomyopathy which were classified 
into ARVC (n=65) and DCM (n=112). I screened for mutations in the following desmosomal 
genes: plakophilin-2 (PKP2), desmoglein-2 (DSG2), desmocollin-2 (DSC2). and plakoglobin 
(JUP). The fifth desmos(lmal gene, desmoplakin (DSP) has been screened by another student 
in the laboratory (Ms Maryam Fish) and the findings have been reported in her MSc thesis 
(Fish 2010). All methods details for phenotyping and genotyping are described in Chapter 2 
(Section 2.4) 
3.3.1 Routine mutation screening in desmosomal genes 
Two genes, DSC2 and PKP2, were screened using a WAVE dHLPC (denatured high-liquid 
performance chromatography) technology (Transgenomic, Irvington, NE). DSG2 and JUP 
were screened using HRJ\l (High resolution melt) with Rotorgene (Corbett Life Science). All 
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amplicons with melting temperature alterations were sequenced on the AB) 3100 automated 
sequencer using the BigDye Terminator v3.1 Cycle Sequencing kit and analyzed using 
BioEdit software (Ibis Biosciences, Carls-bad, CA, USA). 
3.3.2 Identification of novel variants 
There were four online databases used to verify the frequency of variants found in this study: 
1000 Genomes (www.l OOOgenomes.org (25 January2014»; Exome Variant Server (EVS) 
evs.gs.washington.edu: ARVC database (www.arvcdatabase.info 25 January 2014 ) and 
dbSNP database (www.ncbi.nlm.nih.gov/SNP/25January 2014). All of these databases were 
used to identify wheth~r the variant had been previously identified and to obtain allelic 
frequency information. 
3.3.3 Determination of pathogenic significance of variants 
The pathogenicity of rare novel variants was assessed using the polyphen-2 
(http://genetics.bwh.harvard.edu), Sorting intolerant from intolerant (SIFT) (http://sift.bii.a-
star.edu.sg/), and MutationTaster (http://www.mutationtaster.org/ 25 January 2014» 
prediction programmes. Only those variants predicted as disease causing in a protein of 
interest by at least two of the prediction tools were considered for further analysis. I also used 
the Berkeley splice site prediction by neural network tool 
(http://www.fruittly.org/seqtools/splice.htmI29 january 2014» and alternate splice site 
predictor (http://wangcomputing.com/asspjindex.htmI29 January 2014» to predict splice site 
mutations. 
3.3.4 Statistical analysi~. 
Categorical variables are expressed as frequency (percentage) and continuous variables are 
expressed as mean ± SO or median (interquartile range). Gender; age and ethnicity were 
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determined using a Microsoft excel (2010) statistical formulas. Statistical significance was 
performed using Chi-square test; or Student's t-test where appropriate. Statistical significance 
was taken as a two-sidec P <0.05. 
3.3.5 Analysis ofSNPs and disease-causing mutations 
We defined a polymorpr' ism as a variant with a minor allele frequency of:::: I %, using either a 
local study of 232 local population controls or using previously published studies. Individual 
sequence variants were considered disease causing if (I) they were absent in our control 
population and public databases listed under section 3.3.2 above; (2) they segregated with the 
disease where family information was available; (3) they coded for an evolutionarily 
conserved amino acid (ill certain cases); and (4) they were predicted to be pathogenic by at 
least two of the followirg prediction tools: Mutation taster, Polyphen2 and SIFT prediction 
software; or (5) they had been reported previously to cause ARVC and/or DCM. Sequencing 
variants not complying with these criteria were classified as genetic variants of unknown 
significance. All sequence variants were cross-referenced with an online database of ARVC 
mutations (w\vw.arvcdatabase.info 16 February 2014) 
3.4 RESULTS 
3.4.1 Clinical characterist ics of participants with arrhythmogenic right ventricular 
cardiomyopathy 
Between January 2004 and December 20 II, 65 unrelated individuals with a definite 
diagnosis of ARVC were recruited for molecular genetic analysis (Table 3.1). The ethnic 
origin of these 65 index cases was as follows: white South Africans 37 (56.9%), mixed 
ancestry South Africans 16 (24.6%), black South African 8 (12.3%). and Indian South 
Africans 4 (6.2%). The mean age at presentation was 40 ± 15 years and the majority (60.0%) 
were male. Palpitations were the most frequent symptom (67%), followed by dizziness 
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(40%), chest discomfort (26%). and syncope (20%). Table 3.1 compares the baseline 
characteristics of participants with familial disease to those with no history of familial 
disease. There was no sii~nificant difference in the clinical characteristics of probands with or 
without a family history of ARVC. 
Table 3.1: Clinical chaa-acteristics of participants with arrhythmogenic right ventricular 
cardiomyopathy 
Characteristic ·\R\,C Patients P-\alue 
All History of Familial 
Disease 
No History of 
Familial Disease 
No. of Patients (Index cases) (%) 65 (100-0) 16 (24.6) 49 (75.4) 
Gender: 
Male (%) 
Female (%) 
39 (60.0) 
26 (40.0) 
9(56.3) 
7 (43.8) 
30 (61.2) 
19(38.7) 
0.72 
Average age in years (±5W) 40±15 36±14 41 :::::16 0.45 
Ethnici(}': 
Black (%) 
Mixed Ancestry C'Io) 
White(%) 
Indian (%) 
8 (12.3) 
16(24.6) 
37 (56.9) 
4 (6.20) 
2(12.5) 
4 (25.0) 
10 (62.5) 
0(0.00) 
6(12.2) 
12 (24.5) 
27 (55.1) 
4 (8.20) 
0.19 
Presenting symptoms: 
Palpitations (%) 44 (67.7) 9 (56.3) 35 (71.4) 0.23 
Dizziness (%) 26 (40.0) 8 (50.0) 18 (36.7) 0.35 
Chest discomfort or chest pain (%) 17 (26.6) 6 (37.5) II (22.5) 0.39 
Syncope (%) 13 (20.0) 4 (25.0) 9(18.4) 0.83 
Dyspnoea (%) 5 (7.70) 0(0.00) 5 (10.2) NS 
Suddencardiac death (%) 9 (13.8) 2 (12.5) 7 (14.3) 0.81 
Asymptomatic (%) 5 (7.70) 1 (6.30) 4 (8.20) 0.77 
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I 'alues are given as mean Sf); SD. standard deviation: ARI 'C' arrhYfhmogenic right ventricular 
cardiomyopathy: :\'S, not sig,lijicanl. HistOf}, offamilial disease. families with more than one members with 
in/ormation ofARI r disease,1 
3.4.2 Clinical characteristics of participants with dilated cardiomyopathy 
One hundred and twelv\~ unrelated OCM cases were made up of 9 probands (8.1 %) with 
familial disease and 103 probands (91.9%) with no family history of OCM. The participants 
with OCM were predominantly male (69.6%) and of black African ancestry (63.4%). The 
vast majority (75.9%) were in New York Heart Association class III (Ahmed, Aronow et ai. 
2006) done or IV heart failure at presentation. As outlined in Table 3.2, the participants with 
familial OCM were significantly younger (p = 0,001) with smaller cardiac chambers 
compared to those withollt a family history of OCM. 
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Table 3.2: Clinical characteristics of patients with dilated cardiomyopathy 
Chal'acteristic DC'I Patients P-value 
All History of No History of 
Familial Disease Familial Disease 
No. ofPatients (%) 112 9 (8.1) 103 (92.7) 
Gender: 
Male (%) 78 (69.6) 6(66.7) 72 (69.9) 
Female (%) 43 (31.1) 3(33.3 ) 40 (30.1 ) 0.260 
Average age in yrs (mean) (SD) 36+14 28 ::::11 39 ±12 0.001 
Ethnidty: 
Black (%) 71 (63.4) 5 (55.5) 66 (64.1) 
White(%) 6 (5.40) 1(11.1) 5(4.90) 0.140 
Indian (%) 4 (3.60) 1(11.1) 3 (2.90) 
Mixed ancestry (%) 16(14.3) 2 (22.2) 14 (13.7) 
Unknown (%) 15 (13.3) 0(0.00) 15 (14.7) 
NYHA FC (N (%)): 
Class I and II 27(24.1) 2 (22.2) 25 (24.3) 
0.110 
Class III and IV 85 (75.9) 7 (77.8) 78(75.7) 
Heart rate at initial 0.490 
presentation 95.14(\ 9.3) 96.02 (17.9) 94.89 (19.5) 
(beats/ min)(mean(SD)) 
Blood pressure, systolic 102.43 (18.5) 102.37(15.\) 101.78 (18.1) 0.390 
(mmHg) (mean(SD)) 
ECG LBBB (N (%) 34(30.4) 5 (55.6) 29 (28.4) 
0.120 
Echocardiography: 
LVEDD(cm) (mean(SD)) 6.39( 1.80) 6.28 (1.20) 6.84 (1.40) 0.030 
L VEF (em) (mean(SD)) 24.68( 11.5) 28.10 (10.9) 24.68 (11.5) 0.050 
DC\!, dilated cardiomyopathy 5D.· standard deviation: LBBB: lefi bundle-branch block: RBBB. right bundle 
branch block, LI'EDD: left ventricular end-diastolic dimension; U'EF: lefi ventricular ejection fraction and 
XYliA Fe .\'ell' York heart ass )cialion/imctional class 
3.4.3 Desmosomal gene abnormalities in ARVC 
The summary of desmosomal gene mutations found in ARVC patients is presented in Table 
3.3. Of the 65 ARVC patients, 14 (21.5%) carried pathogenic mutations in PKP2 (n 9), 
DSG2 (n = 2), DSC2 (n = I) or JUP (n 2). 
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Table 3.3: Desmosomal gene variants found in 65 cases of ARVC 
I'K1'2 
221 U B M 2146-1 G>C - Imron 10 Spli,c sil, 00 l'athogl'mc (J)~laL James clo/. 2(06) 
192 F W F .:2197­ A7331sX740 II Insertion/Delrllon on J)"1h"n,"~'" 
. ~''''''c''''''''- I (Ddlal, jdllll.:~ e.'1 oi 2uvo, 
::{J:J,,:I\. I\L/\lIlSU 
12 F W M c.II32C>T pQ378X 4 Nonscnse 00 Pathogenic (Watkins. lIendricks el a/ 20(9) 
5.1 12 I. f,U,F& F W 1': M; c.l1h2(,>T p.R388W 4 Missense 00 Pathogenic tWatkins. Hendricks ef al. 20(9) 
192& 38.3 f&M 
51.1 II W M c.2509de1A S837VfsX94 13 Frame shift 00 Pathogenic (Watkins, Hendncks el al. 2(09) 
34 :; U W M c.2540T>C p~L847P 13 Missense 0.0 Pathogenic (Watkins, Hendricks el al. 20(9) 
39.5 I' B F e.1465G>A pG489R 6 Missense 00 Pathogenic (Watkins, Hendricks el al. 20(9) 
[}SG2 
6.1 & 34.5 F&U W M c.1303G>A P D435N 4 Missensc 00 Non­ (Co:\, van der Smagt el (II. 
pathogenic 2(10)as GVUS 
(no 
segregation 
with disease) 
7.1 U W F c.1435A>G p.K479() II Missense 00 Pathogenic Novel 
48 I U B M c.1477A>G P N493S 11 Missense 00 Pathogenic Novel 
DSC2 
53 I II W M c ~587C;>A p (;S63R 16 Missense 00 l'athogel1lc (Cox, van dcr Zwaag el al 
2(11) 
15.1 l! B M c(185(>A p L2271 6 Missense DO GVUS Novel 
c2446G>;\ P V816M 15 Missense 00 (iVUS I Novel 
.lUI' 
31 I lJ W M cA960>A pVltlhM 4 MISsense 00 Pathogenic Novd 
37.1 \I W M c533(,>T p.AlnV 4 Missense 00 Pathogenic Novel 
c.542G>C p.GI8IA Missense 00 GVUS 
161 U W M c. 1910(;>(' p Rh371' II Missense 00 (iVUS Novel 
c.741+2 C>T 
-
14 UTR 0.0 GVUS rs II ~879398 
16.1 &30.1 U&F W M&F c.741+2C>T 
.­
c.....:_____ 14 UTR 
.­
00 GVUS rs I 12879398 
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3.4.3.1 Pfakophilin 2 (PKP2) 

There were 9 (13.9%) probands who had one of 7 pathogenic mutations in the PKP2. Four of 

the probands were of white ancestry and demonstrated a recurrent c.l162T>C change (Table 
3.3). One out of 9 (11.1 %) probands had compound heterozygous mutations (c. 1 1 62T>C in 
exon 4 and c.2197-2202deICACAinsG in exon 11) in the PKP2 gene (Watkins, Hendricks et 
af. 2009). The PKP2 mutations outlined in Table 3.4 were considered to be pathogenic based 
on the criteria listed above. Figure 3.1 illustrates the sequence analysis of the c.1162C>T 
mutation (A), the conservation of the wild type amino acid in evolution (8), and the 
segregation of the mutation with disease in family ACM 38 (C). 
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Figure 3.1: Data that demonstrate a disease-causing plakophilin-2 mutation In a 
proband with ARVC. A, an electropherogram showing an A>T nucleotide substitution; 8, 
amino acids alignment showing mutation conservation infonnation of the amino acid 
affected; C, the segregation of the mutation with disease in family ACM 38. Ptroglodytes 
(chimpanzee) ; Mmulatta (rhesus macaques); Mmusculus (House mouse); Ggallus (chicken); Trubripes (puffer 
fish); D rerio (Zebra fish) ; D melanogaster (Drosophila); C elegans (Nematode); X tropicalis (frogs). 
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Another variant we identified was c.1465G>A (p.R489P), located in exon 6 of PKP2. It is not present in PKP2A 
isoform, which is highly e;.,pressed in human heart tissue (Gandjbakhch. Charron et al. 2011), but occurs in the 
PKP2B isoform. 
All 7 PKP2 mutations dete.:ted in this study are located in the armadillo repeat domain, which is known to play 
an important role in protein folding; disruption in protein folding results in alteration of protein function which 
may result in cardiomyopalhy (Kirchner, Schuetz el al. 2012). 
3.-1.3.2 Desmoglein 2 (DSG2) 
In DSG2, two novel muta!lons were identified in two unrelated probands (3.1 %); these were missense mutations 
in exon II (c.1435A>G and c.1477A>G). Unfortunately, the probands had no family members available for 
screening. The mutations were not found in ARVC database, 1000 genomes, NCBI dbSNPs and 232 popUlation 
controls. They were predicted to be damaging and disease causing by three bioinformatic prediction tools: 
Polyphen2: SIFT and Mut:ltion taster. The mutations both code for amino acids located in extracellular cadherin 
(EC) region of the protein 
The c.1435A>G mutatiolJ codes for p.K479Q, and is associated with the substitution of a conserved polar 
uncharged amino acid (Iy;ine) with a polar basic (glutamine) type. 
The c.1477A>G mutation, results in a change of asparagine (a polar amino acid) to serine (a neutral amino acid) 
(p.N493S). The extracellular region is responsible for desmoglein/desmocollin protein interactions 
(Gehmlich, Asimaki et al. 20 10), and the alterations caused by these amino acids changes 
were predicted to have a deleterious effect on protein function. 
Additionally, a missense mutation (c.1303G>A; p.D435N) was identified in exon 10 of 
DSG2 in two unrelated individuals. Although this variant affects a conserved amino acid and 
was not found in 232 population controls, it did not segregate with disease in a family that 
was studied. It was reported previously (Cox, van der Smagt et al. 20 I 0) to be a variant of 
unknown significance and was predicted to be non-pathogenic by the Mutation Taster 
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prediction tool. Therefore, we provide additional evidence that c.1303G>A is not a disease 
causing variant in ARvc. 
3.4.3.3 Desmocollin 2 (DSC2) 
One of the 65 pro bands 0.5%) with ARVC had a missense mutation c.2587G>A (p.G863R) 
in exon 16 of DSC2. This mutation was reported as disease causing (Cox, van der Zwaag et 
al. 20 II). It was als,) predicted by Mutation taster, Polyphen2, and SIFT to be causing 
deleterious mutation and was not found in 232 population controls. Family members for this 
proband were not available to assess segregation with the disease. This mutation is located in 
the intracellular cadnerin segment (ICS), which is well conserved in cadherins and is 
responsible for the interactions of the other desmosomal proteins with cadherins (Gehmlich, 
Asimaki et ai. 20 I O\. The extracellular domains contribute to the interactions of cadherins 
with other cadherin proteins, e.g. interaction of desmoglein with desmocollin proteins 
(Kirchner, Schuetz el al. 2012). 
Two novel genetic variants of unknown significance (GVUS) were identified: a missense 
variant c.685C>A (p.L227I) in ex on 6 and another missense variant c.2446G>A (p.V816M) 
in exon 15 in the same index case. The c.685C>A variant was predicted by Mutation taster to 
be a polymorphism, by Polyphen2 to be damaging, and by SIFT to be tolerated. The 
c.2446C>A variant was predicted by Mutation taster to be a polymorphism, by Polyphen2 to 
be benign, and by SIFT to be tolerated. The variants were not present in 232 population 
controls and databases. The second variant, c.2446C>A, was predicted not to have a 
damaging effect b} all prediction tools, and there were no samples from family members to 
investigate regarding segregation with disease. Thus we classified both variants as GVUS. 
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3...1.3.-1 Plakoglobin (JUP) 
In JUP, there were two pathogenic mutations identified in two separate probands (3.1 %): a 
c.496G>A missense mutation (p.VI66M) in exon 4, and a c.533C>T missense mutation 
(p.A I 78V) in exon 4 ill 2 unrelated individuals. Both of these mutations were novel, coded 
for a conserved amino acid, and were absent in 232 population controls as well as SNP 
databases. The p.V166M mutation changes valine to methoinine and both amino acids belong 
to non-polar amino acids. The variant was predicted by Mutation taster to be disease causing; 
Polyphen2 and SIFT also predicted the change to be damaging. The p.A 178V mutation 
changes a polar amino acid (arginine) to non polar amino acid (valine). The arginine is 
conserved among m<)dern animals and the variant was not detected in 464 control 
chromosomes, dbSNP, 1000 Genomes and ARVC databases. The variant was predicted to be 
disease causing by Mlltation taster; predicted to be damaging by Polyphen2 and SIFT. There 
were no family members available to test for segregation of the variant with the disease. The 
two mutations are located in the armadillo repeat domain of JUP. 
Additionally, three non-pathogenic variants in JUP were detected. The first was a p.G 181 A 
missense mutation identified in exon 4 ofJUP in ACM 37.1 was predicted by Mutation taster 
to be a polymorphism; Polyphen2 predicted it to be benign and SIFT predicted it tolerated 
change. The second variant was a p.R637P missense mutation in ex on 11 of JUP and was 
predicted by Mutatio() taster to be polymorphism, by SIFT to be tolerated, and by PoIyphen2 
to be benign. The last variant was a reported c.*2C> T (rs 112879398) variant identified in 
exon 14 of untranslated region (UTR) of JUP in two unrelated probands, ACM 16.1 and 
ACM 30.1. The variant is not predicted by splice site prediction tool by neural network to 
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cause any effect on tne splice site regIon. In the 1000 Genomes database and dbSNP 
database, it is described as having a minor allelic frequency of 0.005. These variants were not 
found in our 232 population controls. Thus we concluded that p.G 181 A and p.R637P were 
GVUS and rs 112879398 was likely to be a polymorphism. 
3.4.4 Oesmosomal gene abnormalities in OCM 
The summary of desmosomal gene mutations found in OCM patients is presented in Table 
3.4. In 112 probands, there was only one mutation in PKP2, a c.2540T>C (p.L847P), which 
was considered by us to be pathogenic in ARVC (Watkins, Hendricks 2009). However, this 
mutation did not show segregation with disease within this OCM family (Figure 3.2). We 
provide strong evidence that this mutation is not pathogenic in OCM, and its pathogenicity in 
ARVC needs further confirmation through family studies. A missense GVUS was identified 
in DSC2 (p.V816M). the proband had no history of familial OCM. Finally, a known rare 
polymorphism, c.741+2 C>T (c.*2C>T) (rsl 12879398) was identified in the 3' UTR ofJUP 
in three probands \\ ith OCM. It was not predicted to alter the splice site by splice site 
prediction tool. 
J2} ~--d) (f) dJ) 
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Figure 3.2: Family OCM 3 illustrate no segregation of variant T2540C 
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3.4.5 Oesmosomal gene polymorphisms common to ARVC and OCM 
There were 14 polymorphisms identified in OCM patients as well as ARVC patients, 
including: PKP2 (n=3). DSG2 (n=4), DSC2 (n=5) and lUP (n=2) (Table 3.5). The two novel 
SNPs in PKP2 and lUP are in the process of being registered in the SNP database (dbSNP). 
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Table 3.4: Desmosomal gene mutation and genetic variants of unknown significance (GVUS) found in 112 cases with DeM 
Gene Index case II> Familial Ethnicity Gender Nucleotide Amino Exon Type Frequency Classification Reported 
change acid preyiously 
PKP2 
3.5 IF IB 1M I c.2540T>C I p.L847P , 13 
I !~issens I0.0 INon- I(Watkins, 
pathogenic Hendricks et 
' al.2009)(no 
segregation 
with disease) 
I I 
DSC2 
-L-
Missens I 0.0 I GVLJS I Novel 
e 
55.\ 
JUP 
ILJ IB 1M I c.2446G>A 
I I I I 
I p.V8\6 
82.\;303.1&333.\ ILJ IB 1M I c.74\+2 
C>T 
F: familial; and U: undertermined 
15 
1M 
UTR Splice 
site 
10.0 I GVUS I rs 112879398 
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Table 3.5: Desmosomal gene polymorphisms common to both ARVC and DCM cohort members (SNPs) 
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3.5 DISCUSSION 
This is the first report of the frequency of desmosomal gene mutations in South Africans with 
ARVC and OCM. This chapter shows that desmosomal gene mutations are common in 
patients with ARVC (at least 21% of cases) than those with OCM (no pathogenic mutation 
observed in PKP2, DS( '2, DSG2 and JUP). The c.2540T>C (p.L847P) mutation in PKP2 that 
has been associated with ARVC proved not to be pathogenic in OCM, suggesting that its 
pathogenic role in ARVC needs confirmation by further testing. Our study detected 3 out of 8 
black South Africans Ci7.5%) with potentially disease mutations in ARVC. 
3.5. J The frequency of desmosomal gene variants in ARVC compared with other studies 
PKP2 mutations hav.; been reported to be more common as compared to the other 
desmosomal gene mutations in patients with ARVC. Recent studies have shown that PKP2 
(which in this study had a prevalence rate of 13.9%) is the most common gene implicated in 
ARVC, followed by nsp or DSG2, then DSC2 and JUP (Bauce, Nava et al. 2010, Rigato, 
Bauce et al. 2013), the prevalence of OSC2 and JUP is no statisticalIy significant but it is 
mentioned to shown 11 picture of the direction of these genes results. The frequency of DSP 
mutations was 3% (3/62) in our ARVC cohort (Fish 20 J 0). In the present study, both DSG2 
and JUP genes accounted for 3.1 % of cases, and DSC2 1.5% of cases. We did, however, find 
JUP variants to be more common than DSC2 variants, in contrast to other studies (Bauce, 
Nava et al. 20 I 0, Rig,ito, Bauce eJ al. 2013), although our results are not statistical significant 
3.5.2 The frequency of desmosomal gene variants in OCM compared with other studies 
A previous study from our laboratory revealed a deleterious mutations in the desmoplakin 
(DSP) gene in 6/150 (4%) patients with OCM (Fish 20 10). The screening of four additional 
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desmosomal genes -PKP2, DSG2, DSC2. and JUP - did not identify an unequivocally 
pathogenic mutation that causes OCM. The frequency of desmosomal gene mutations in 
OCM of approximately 3% is similar to the findings of Elliott et al in the UK (Elliott, 
O'Mahony et al. 2010). However, PKP2 mutations were the dominant cause of OCM in the 
UK cohort, whereas DSP mutations were the dominant cause in our South African cohort 
(Fish 20 I 0). 
3.5.3 Phenotypic variation arising from identical desmosomal gene mutations 
It is well established that mutations in one gene can result in different types of 
cardiomyopathies (i.e., phenotypic heterogeneity). It has been shown that sarcomeric gene 
mutations may be associated with both hypertrophic cardiomyopathy (HCM), OCM and 
restrictive cardiomyopathy (RCM) (Watkins, Ashrafian et al. 20 I I). Identical tropin I 
mutations can lead to a phenotype of RCM and HCM in the same family (Mogensen, Kubo et 
al. 2003). There was no evidence, however, of phenotypic heterogeneity in our study. 
Recently, other investigators have shown that mutations detected in OCM patients have been 
reported with the ARVC phenotype, but their clinical features did not fulfil the recently-
modified criteria for the diagnosis of ARVC (Garcia-Pavia et al 2013). In their patients with 
familial OCM who had desmosomal mutations, (Garcia-Pavia, Cobo-Marcos et al. 
20 I 3)Garcia-Pavia et ai. found no correlation between presence of a mutation and fibrofatty 
changes in the myocardium, which led them to challenge the histological criteria for the 
diagnosis of ARVC (Garcia-Pavia et al 2013). Furthermore, other investigators reported 
lethal desmosomal mutations in sudden death patients with none of the pathological features 
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of ARVC, and they suggested that the link between desmosomal mutations and ARVC be re-
evaluated (Zhang. Tavora et al. 2012). 
3.5.4 Mutation hotspots in ARVC gene mutations 
The location of disease-causing mutations in DSG2, DSC2, and JUP follow the expected sites 
of mutation hotspots in ARVC. Pilichou and his colleagues have shown mutation hotspots are 
located in extracellular domains of DSG2 (Pilichou, Nava et al. 2006); likewise the mutations 
we identified were located in the same region of the gene (Figure 3.3A). 
In DSC2, reported mutation hotspots are located in the region of the gene coding for the 
extracellular domain and the C-terminus (Awad, Calkins et al. 2008). The mutations that 
were identified in our study were detected in extracellular domain, and there was also one 
reported mutation thal was found in the intracellular cadherin specific (lCS) region as 
described above (Figuf<~ 3.38). 
In JUP, mutation hotspots are located in the region of the gene coding for the N-terminus and 
armadillo repeat units; (Awad. Calkins et al. 2008) our mutation was identified in the 
armadillo repeat units (Figure 3.3C). No specific mutation hotspots have been described in 
PKP2; this study identified mutations in the N-terminus and armadillo repeat units. Other 
authors have suggested that these are the functional domains of the gene (Awad, Calkins et 
al. 2008) (Figure 3.301. It is remarkable that the GVUS and rare 3' UTR polymorphism were 
also observed with both cases of cardiomyopathies (Figure 3.2).The desmosomal gene 
mutations implicatedn OCM are found in the same regions of the genes where ARVC 
mutations are also located. 
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A. c..mogleln 2 
Figure 3.3: Desmosomal gene domains affected by mutations in cardiomyopathy 
SS: signal peptide sequence; Pro. propeptide; ECI-4: extracellular domains 1-4; EA: extracellular anchor; 
TM· transmembrane domain; fA : intracellular anchor; 1CS: intracellular cadherin segment; 1PL: intracellular 
proline-rich linker, RUO: 6 repeated-unit domains; OTO: desmoglein-specific terminal domain and in 
plakophilin-2 and plakoglobin, 1-/3 stands/or armadillo repeats units 
Black arrows: ARVC mutations; blue variants: ARVC genetic variants 0/ unknown; green variants: OCM 
genetic variants o/unknown significant; red variant: OCM mutation 
3.5.5 Potential roles for polymorphisms in disease pathogenesis 
[ have clarified the status of two GYUS in this study (results section 3.4.3.1 and 3.4.3.2). The 
first, a c.l303G>A (p.D435N) variant in DSG2, was previously reported as a GYUS 
associated with ARYC (Cox, van der Smagt et al. 2010). [n our study, there was no 
segregation of this GYUS with ARYC, which suggests that it is a non-pathogenic mutation 
in ARYC. The second, a c.l051A>G (p.S35IG) variant in DSG2, was previously reported 
(Quarta, Muir et al. 2011) as a GYUS. We determined this to be a SNP according to data 
from the 1000 Genomes and dbSNP databases (rs 139326669). 
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There were 12 SNPs (IUt of 14 polymorphisms identified in desmosomal genes in this study 
(Table 3.5). Many SNPs in certain genes have been associated with the disease phenotypes by 
modifying gene expression and imparting allelic expression imbalance (Stranger, Nica et al. 
2007, Cunnington, Santibanez Koref el al. 2010, Schaub, Boyle et al. 2012). However, to 
date, no studies of the impact of SNPs on gene expression have been performed in 
desmosomal genes that cause ARVC. In chapter 5, we describe the results of the first allelic 
expression imbalance study based on 3 of these SNPs. Since c.1465G>A (p.R489P) in PKP2 
was detected exclusively in ARVC patients, we propose this variant to be pathogenic via 
other mechanisms, such as aberrant splicing or allelic- specific down regulation at the mRNA 
level (Gandjbakhch, Charron et al. 2011). 
3.5.6 Limitations and fUlure directions 
We have not yet performed functional studies on the putative pathogenic gene mutations 
reported in this work. Incorporation of individual mutations in cellular and animal models 
could help to demostrate their role in disease pathogenesis. An additional limitation is that to 
date we have only screened cardiomyopathy patients who fulfilled the Task Force Criteria for 
ARVC; it is possible thar other patients who do not meet the criteria could have desmosomal 
gene mutations. Furthermore, this study was too small to establish whether there are any 
differences in the distribution of mutations in the desmosomal genes between the two types of 
cardiomyopathies. Finally, there is a need for extension of the pedigrees and genetic 
screening in cardiomyop3thy families and to compare clinical features and outcomes over 
time. This will be especictlly helpful in cases where mutations did not clearly segregate with 
disease or where family member samples were unavailable for the present study. 
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3.6 CONCLUSIONS 
There are three major observations from this chapter. First, taken together with the findings 
of DSP screening which were reported elsewhere, desmosomal gene mutations account for 
about 25% of ARVC cases and 3% OCM cases. Elsewhere, desmosomal gene mutations are 
found in up to 50% of probands with ARVC (Basso, Corrado et al. 2012). The relatively low 
yield in this South African cohort for both ARVC and OCM may not be sufficient to justify 
clinical testing for these mutations in routine practice. Second, pathogenic mutations in 
desmosomal genes are an uncommon cause of OCM in South Africa. Finally, we have 
identified four apparemly unrelated individuals with an identical mutation in PKP2. The 
occurrence of recurrent mutations in the probabnds with ARVC and OCM, provides an 
opportunity for the study of a potential founder effect, as described in the following chapter 
4. In the future, the identification of large numbers of individuals with an identical mutation 
on a common haplotype background could provide a resource for genotype-phenotype 
studies. 
95 
Chapter 4 
Investigation of the recurrent PKP2 c.1162C>T variant as a founder mutation 
4.1 INTRODUCTION 
In the previous chapter, I identified a recurrent PKP2 c.l J62C>T (p.R388W) mutation in 
four unrelated proband~,. The mutation was first reported previously by our group (Watkins, 
Hendricks et al. 2009) and subsequently by (Xu, Yang et al. 2010); in all instances, the 
mutation occurred in individuals of white ancestry. The recurrent c.1162C>T (p.R388W) 
mutation in exon 4 of PKP2 codes for an amino acid located in the armadillo repeat unit 2 of 
PKP2 (Figure 4.1). Thr four unrelated individuals with the recurrent PKP2 mutation were 
white South Africans of European origin. This clustering of the recurrent mutations in this 
ethnic group raised the possibility that the mutation may have arisen on a common haplotype 
background due to a common ancestor (i.e., a founder effect). Afrikaans-speaking white 
South Africans and people of mixed ancestry are known to have a high prevalence of 
inherited conditions due to founder effects, such as Fanconi anemia caused by mutations in 
the rANCC gene (Tipping, Pearson et al. 2001); hypertrophic cardiomyopathy due to 
mutations in the lv1YH7 gene (Moolman-Smook, De Lange et al. 1999); long QT syndrome 
due to mutations in the KCNQCl gene (Brink and Schwartz 2009); and familial 
hypercholesterolemia dU\:' to mutations in the LDLR gene (Jelassi, Slimani et al. 2011). 
Recurrent mutations (i.e. the exact same mutation observed in two or more unrelated patients) 
are either the result of repeated de novo events (usually in the context of 'mutational 
hotspots' in the genome) or amplification in a population through vertical transmission from 
a common ancestor, kno\A'!1 as a founder effect (Memer, Hodgkinson et al. 2008). One of the 
most recently discovered ARVC gene (TMEM43)(Memer, Hodgkinson et al. 2008) was 
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identified on the basis of linkage to chromosome 3p25 and a recurrent missense mutation 
(c. I 073C>T: p.S358L) that was exclusively found in patients across 15 unrelated ARVC 
families from the island of Newfoundland, a Canadian founder population of ~51 0 000 
people of English and Irish extraction (Mannion 1977). This strong founder effect was 
instrumental in pinpointing a missense mutation as causative, given that TMEM43 was 
previously unassociated with human disease and there was no available functional assay 
(Haywood, Merner et af. 2013). The disease haplotype was reconstructed by genotyping 
polymorphic markers spanning the critical region on 3p25 in patients, which identified a 2.36 
Mb shared ancestral haplotype across these 15 families. This powerful approach allowed 
clinical studies on 257 patients with the same mutation, which show that ARVC due to 
c. l 073C>T:p.S358L is particularly lethal (Merner, Hodgkinson et af. 2008). 
If another founder effect with a large number of affected families is identified through this 
work, then it will provide an extended platform for genotype-phenotype correlations in 
ARVC. 
Hypothesis 
I hypothesized that the recurrent c.1162C>T (p.R388W) PKP2 mutation identified in these 
four ARVC probands of white South African ancestry was a founder mutation. 
p.R388W p.A733fsX740 p.S837VfsX9 
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Figure 4.1: Schematic representation of PKP2 domains and mutations described in this 
thesis. Grey boxes represents Nand C domains, respectively, and yellow boxes represent 
armadillo repeat units. 
4.1.1 Study aim 
The aim of the study was to use microsatellite markers and single nucleotide polymorphisms 
(SNPs) to derive haplOlypes for 4 probands and their families with the recurrent PKP2 
mutation c.1162C> T (p. R388W) in order to determine whether this mutation occurred on a 
common haplotype background or not (i.e., represents a founder effect). 
4.2 METHODS 
4.2.1 Phenotyping 
The phenotyping and diagnostic evaluation of participants in the ARVC Registry of South 
Africa are described in full in chapter 2 (Section 2.4). Of the 4 probands with the recurrent 
PKP2 c.1162C>T (p.R:;88W) mutation (i.e., ACM 5.1, ACM 12.1, ACM 19.2 and ACM 
38.3), two had first-degree relatives who were available for further study (i.e., ACM 19.2 and 
ACM 38.3). In family ACM 19, the recurrent mutation was transmitted by the affected 
mother (ACM 19.6) to atTected children (ACM 19.1; 19.2 and 19.4) (Figure 4.2). 
98 
196193 
c.1162T>C 
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c.1162T>C c.1162T>C c.1162T>C 
Figure 4.2: ACM 19 family pedigree 
In family ACM 38, the recurrent mutation was transmitted by the affected mother (ACM 
38.2) to the affected children (ACM 38.3 and 38.5) (Figure 4.3). 
38.1 
c.1162C>T 
384 383ft 385 
c.1162C>T c.1162C>T 
Figure 4.3: ACM 38 family pedigree 
4.2.2 Haplotyping 
I sought to determine whether individuals carrying the recurrent mutation in PKP2 share a 
common ancestral haplotype. Microsatellite markers across PKP2, spanning a 300-kb region 
on chromosome 12 (NC ~000012.10), were genotyped in the four affected ARVC index cases 
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as well as in the first-degree relatives of two index cases with family members available for 
genotyping. A single, published, intragenic marker, present in exon 7 (0 12S 1692) of PKP2, 
was genotyped along with two unpublished flanking markers (PKP2_5'_ CA 1 and 
PKP2_3' TGl) on the ABr sequencer. Two other variants (TI097C and 2197-
2202dellCACACCinsG mutation) were genotyped, for a total of five markers across the 
PKP2 locus. Results were analyzed using GeneMapper software v3.0 (Applied Biosystems). 
The most probable haplolypes were constructed manually based on pedigree data and marker 
positions. rn the two cases for which only the proband was available for genotyping, an 
"assumed" haplotype (Moolman-Smook, De Lange et al. 1999), based on the haplotype 
identified by family mapping, was generated. Fifty ethnically matched controls selected from 
232 population controls were screened for this disease haplotype. 
4.3 RESULTS 
The results of the haplot) ping are presented in Figure 4.4. A specific haplotype, based on five 
markers (three microsatt'llites and two variants), was present in the unrelated index cases 
(ACM 5.1. ACMI2.1, ACMI9.2 and ACM 38.3). The common PKP2_5' CAl_12-1097_T-
1162_T-DI2SI612_2-DELlINS_WT PKP2_3'_TGI_3 haplotype is represented in yellow in 
Figure 4.4 A-D. This disease-associated haplotype was not detected in the 50 ethnically 
matched population controls. These data suggest that the recurrent mutation is identical by 
descent in two families. According to the assumed haplotype, the 2 unrelated probands with 
no relatives (ACM 5.1 and ACM 12.1) appeared to be identical by descent to the other two 
families CACM 19 and ACM 38). This common haplotype with the recurrent mutation 
accounts for 28.6% of A RYC chromosomes in the nine apparently unrelated individuals with 
a PKP2 mutation. The father's phenotypes information has been added in my thesis. He 
presented shown no symptomps of ARYC at first and as the times goes he he developed a 
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mild phenotypes and he was found having a reported PKP2 mutation (A 733fsX740 ) in exon 
II. 
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Figure 4 .4: Haplotype results for ACM families with recurrent mutations. Black boxes and 
circles represent severely affected males/females (including stroke marks for deceased 
patients), and the yellow bar represents the haplotype that segregates with the recurrent 
mutation. 
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4.4 DISCUSSION 
I have identified an identical mutation with a common haplotype that was present in four 
apparently unrelated individuals with a recurrent PKP2 mutation. These four individuals were 
white South Africans of European ancestry and probably descended from a common 
unidentified ancestor (i.e .. a founder effect). To date. this is the first report of a founder 
mutation in South Afric;ms with ARVC. The observation of founder mutations in PKP2 was 
first made in the Netherlands, where four different recurrent mutations were present on 
identical haplotype backgrounds (van Tintelen, Entius el al. 2006). and subsequently in 
Newfoundland (Merner. Hodgkinson el al. 2008). It is of interest that the majority of white 
South Africans are of Dutch origin, but the founder mutation that is present in the South 
African cohort is unique to the South African population. 
The founder effect in South Africa likely results from the fact that a small group of Dutch 
people harbouring a variety of rare, single gene diseases originally settled in the Western 
Cape Province in 1 t h century (Moolman-Smook, De Lange et al. 1999) and later migrated to 
the hinterland of Sout~ Africa. Those single gene diseases were kept in their population 
which behaved as a population isolate due to their perceptions of origin, culture and religion 
(Brink and Schwartz 201)9). 
The c.l162C>T (p.R38};W) mutation, initially identified in ACM 5.1; 12. [ and 19.2 (Chapter 
3 Section 3.3.5.1), is ;I rare mutation and was not observed in 464 chromosomes. The 
mutation is located in the armadillo repeat domain and is known to play an important role in 
protein folding. due to a missense c.1162C>T, p.R388W recurrent mutation PKP2 may 
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become unstable due to PKP2 unfolding (Wimley and White 1996). Arginine is hydrophilic 
whereas tryptophan is hydrophobic, a change that may adversely affect PKP2 protein 
function. This study revealed that haplotype analysis across PKP2 (12p21) in two families 
(ACM 19 and ACM 38) and assumed haplotype (Moolman-Smook, De Lange et ai. 1999) in 
individuals (ACM 5.1 an,j ACM 12.1) carried the same mutation also shared either a disease-
associated haplotype or a haplotype that was assumed to be disease-associated. This disease-
associated haplotype was not detected in 50 ethnically matched population controls. Our data 
are consistent with the aossibility that recurrent mutation is identical by descent in two 
families and we assumed that two unrelated individuals with no relatives had the same 
disease-associated haplotype by descent. 
The discovery of the founder effect has important implications for the molecular investigation 
and study of ARVC in South Africa. In the present study, the PKP2 c.1162C>T (p.R388W) 
mutation accounts for 28.6% (4114) ARVC cases with a desmosomal protein gene mutation. 
A simple restriction enzyme test for restriction fragment length polymorphisms is available 
for the identification of the founder mutation. Therefore, all new index cases entering the 
ARVC Registry of South Africa will be screened for this particular founder mutation prior to 
embarking upon full examination of PKP2 and other desmosomal protein genes. 
4.5 Limitation and future work 
In two of the four probands. there were no family members available for the study, so 
haplotypes had to be created based on assumptions (imputing). Extension of screening to 
those probands' family members will be necessary to confinn our results. It will also be 
necessary to perform functional studies to investigate the effect of this recurrent mutation on 
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gene expression and protl~in function. In the future, screening of a large ARVC cohort to find 
more desmosomal founder effects could also be performed and could simplify the molecular 
diagnosis for clinical use. Finally, a large number of families with founder effects will be 
needed to create a platform for genotype-phenotype studies in ARVC (Merner, Hodgkinson 
et al. 2008). 
4.6 Conclusion 
I have identified a new founder mutation in PKP2 in four families with ARVC. All patients 
with ARVC of white Scuth African ancestry should be screened for this mutation prior to 
embarking upon the study of the genetic mutations that cause ARVC. These four families 
should be extended and new families sought in order to provide a large panel of cases of 
ARVC with the same mutation on a common haplotype background for genotype-phenotype 
studies. 
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Chapter 5 
Investigation of desmosomal gene allelic expression in peripheral blood 
5.1 INTRODUCTION 
In chapter 3, I identified 14 single-nucleotide polymorphisms (SNPs) in both ARVC and 
DCM patients. While not directly pathogenic, some SNPs are known to modify the 
phenotype of a disease (Cunnington, Kay et al. 2009). Previous studies have demonstrated 
that heterozygous SNPs have a cis-effect that is indicated by unequal amounts of transcript 
from each allele, (Cunnington, Kay el al. 2009) e.g. in diseases such as cancer and 
cardiovascular disease (Chen, Weaver el al. 2008, Cunnington, Kay el al. 2009), In some 
cardiomyopathies, an allelic expression imbalance (AEI), which is an allelic imbalance in 
gene expression caused by a variant in one of the alleles. has been reported; e.g., a case-
control study of DCM padents identified a rs 1739843 polymorphism in intron 2 of H5pB-7, 
which encodes the small heat shock protein cyHSP associated with OCM susceptibility 
(Brenner, Johnson el al. 2000, Marian and Belmont 20 J J). To study the effect a SNP has on 
gene expression, it must be common in population controls, with a minor allelic frequency of 
at least 5% (Stranger, Nica el al. 2007, Cunnington, Kay el al. 2009, Cunnington, Santibanez 
Koref et al. 2010). In ~he 14 cardiomyopathy SNPs [ identified, 3 single nucleotide 
polymorphisms (SNPs) in 3 desmosomal genes (PKP2; DSG2; and DSC2) met this criterion. 
Hypothesis 
I hypothesized that the eligible PKP2 SNPs , detected in 3 cardiomyopathy cases (rs 1046116; 
DSG2, rs79241126 and DSC2, rs686333) have a cis-regulatory effect that may modify the 
ARV C phenotype. 
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5.1.1 Study aims 
This chapter seeks to investigate the cis-effects and total gene expressIOn of the above 
mentioned exonic SNPs in peripheral blood to understand the association between these SNP 
genotypes and gene expression. 
5.2 METHODS 
Detailed methods and selection of cardiomyopathy patients SNPs who met the criteria for 
gene expression is presented in chapter 2 (section 2.6). 
5.2.1 Selection of participants 
For this study, two diffe"ent sets of population controls were used: the South African (SA) 
cohort recruited in Cape Town, South Africa, and North East (NE) cohort recruited from 
Newcastle in United Kingdom. The SA participants were anticipated to exhibit greater 
genetic diversity as compared to European subjects. (Cunnington, Kay et al. 2009, Tishkoff 
SA, A et al. 2009). The cohort recruitment process is described in greater detail in Chapter 2 
(section 2.6). 
5.2.2 Selection of heterozygous SNPs 
Three of the desmosoma genes that were screened had 3 SNPs with a minor allelic frequency 
that was greater than 5%. These SNPs were selected for investigation of allelic expression 
imbalance. In P KP2, located on chromosome 12, rs I 046116 identified in ex on 4 was selected 
(minor allele frequency 42%); in DSG2. located in chromosome 18, rs79241 126 in exon 14 
was chosen (minor alleJ,~ frequency = 12%) and in DSC2, also located in chromosome 18, 
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rs868333 was detected in exon I and chosen for the study (minor allele frequency = 23%). 
The location of desmosomal SNPs of interest is illustrated in Figure 5.1. 
PKP2: Plakophilin-2; DSG2: Desmoglein-2; DSC2: Desmocollin-2, white box: untranslated region; blue box. 
exons and rs no.: reference no. for a SNP ofinterest, Red boxes denote identified mutations and blue boxes 
denote SNPs of interest in this study 
Figure 5.1: Desmosomal structural genes showing mutations and regions of SNPs of interest 
5.2.3 Investigation of gene expression in peripheral blood 
In order to investigate allele expression imbalance (AE!), I only used samples from study 
subjects who were heterozygotes for the SNP in question. Because I used peripheral blood 
samples rather than cardiac tissues to obtain RNA for my genetic studies, it was important to 
confirm that the genes harbouring the SNPs of interest are expressed in RNA found in the 
peripheral blood. 
In respect to total gene expressIOn USIng North East cohort, genotyping of the SNPs of 
interest was carried out by Applied Biosystems TaqMan genotyping assays. Quantitative 
Real-time PCR reactions were carried out using TaqMan gene expression probes assays and 
reagents from Applied Biosystems (USA) and were performed through the 7900HT Real-
time PCR System (Applied Biosystems, USA). Relative total gene expression was analysed 
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using the comparative cycle threshold (Ct) method using SDS Software v2.3 and RQ 
Manager 1.2 softwar;: (Applied Biosystems, USA) according to the manufacturer's 
instructions. 
AEI genotyping of the SA population controls were performed to discriminate heterozygotes 
samples using real-time PCR as described above. Artificial heterozygotes were also made 
with genomic DNA from homozygotes of both major allele and minor allele to test the 
reliability of the Sequenom assays. The gDNA homozygotes were mixed in the following 
ratios (major allele: minor allele): 8:1; 4:1; 2:1; 1:1; 1:2; 1:4 and 1:8. In both mixed gDNA 
(artificial heterozygotts) and cDNA samples, a concentration of 25ng/ul for each sample in 
our SA cohort was sent to Dr Christine Blancher who is Project Manager in High Throughput 
Array Facility. (High throughput genomics) in Welcome Trust Centre for Human Genetics 
(Oxford,UK) to quanl ify the samples using the Sequenom platform. Quantification of the 
allelic expression ratio was done by primer extension and MALO 1-TOF mass spectrometry. 
Amplification of gDNA with purification of products was performed in replicates of 4. 
5.3 RESULTS 
5.3.1 Investigation of gene expression in peripheral blood 
In DSC2, both cDNA and gDNA were amplified and products were detected at position J 093 
base pairs (bps) for gDNA and at position 140bp for cDNA PCR products. In DSG2, cDNA 
and gDNA were amplified and only gDNA was detected (indicated by a band at 305bp) but 
cDNA amplification revealed no band at position 171 bp. These findings suggest a lack of 
expression of DSG2 i1 blood and that led to its exclusion from the experiment. 
In the case of PKP2. four gDNA bands were seen, including an expected band at position 
643bp, showing non-specificity of PKP2 primers. These primers were optimised in cDNA 
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and only one band was detected at the expected size. cDNA amplification products revealed a 
faint or weak band in the agarose gel at position 267 bps. Gene expression results are 
presented in Figure 5.2. 
Figure 5.2: Gene expression in peripheral blood: In this figure, three genes are investigated 
and represented by numbered boxes: I) DSC2; 2) DSG2 and 3) PKP2, Lane I of each gene 
contains a marker to measure the size of PCR products; lane 2 is a blank to eliminate 
contaminators; lane 3 contains the cDNA PCR product; lane 4 contains the gDNA PCR 
product. 
5.3 .2 Whole gene expression investigation in PKP2 rs 1046116 
5.3.2.1 Genotyping results 
Infonnation on the selected desmosomal gene SNPs is summarised in Table 5.1. There were 
182 NE cohort participants who were genotyped successfully for PKP2 at the rs1046116 
SNP: 115 were homozygous for the major allele, 59 were heterozygous, and 8 were 
homozygous for the minor allele. The minor allele frequency (MAF) found in white controls 
was similar to that of the Caucasian (CEPH) HapMap cohort (CEU) published in NCBI; SNP 
genotypes had a MAF of 0.20 while CEU, NCBI dbSNP had a MAF of 0.24. 
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All 192 white individuals from the NE cohort who were genotyped for DSC2 rs868333 
demonstrated only the wi d type alleles (i.e., the SNP was not present). DSC2 custom probes 
from Applied Biosystem failed to work in the SA Black ethnicity cohort, so no results could 
be obtained. DSG2 was not detected in the blood during the gene expression investigation, so 
no further studies were ce.nducted on the gene. Thus, total gene expression studies were only 
conducted on the PKP2 S'JP. 
Table 5.1: Identified minor allelic frequencies (MAF) from allelic genotyping 
South African Caucasian 
Gene SNP lD Chr. no. Genotype SAMAF NCBt YRl 
MAF 
NEMAF NCBICEU 
MAF 
PKP2 rsl046116 12pll T:C 0.190 I 0.195 0.200 ! 0.240 
DSC2 rs868333 J8q12.1 T:C 0.12 0.466 0.0 ! 0.110 
DSG2 Rs79241126 J8q12.1 A:G 
- - -
0.05 
SSP: single nucleotide polymo'phism: Chr: chromosome: no,: number: SA: SOUlh Aji'ica: '\fAF: minor allelic 
frequency: ,\E: Sorth East emted kingdom; PKP2: plakophilin-2; DSC2: desmocollin-2, DSG2, desmoglein-2; 
,\CBI national centre for biott'chnology information; YRI J'oruba in Abadan, '\igeria and CEU' Utah 
residents with ancestlyji'om .\rJl'thern and IVestern Europe 
5.3.2.2 Variability ofPKl'2 total gene expression 
Total gene expression for PKP2 indicated variability within individuals by 64-fold for the 
SNP rs 1046116. A plot or the normalised total gene expression crossing threshold (et) values 
is shown in Figure 5.3. Ct value is a number of cycles taken for each reaction to reach an 
arbitrary amount of f1uor~scence that in turn is used to generate a relative expression level 
(VanGuilder, Vrana et ai. 2008). Furthermore, the standard error on total gene expression 
was high. suggesting that PKP2 gene expression was weak in blood eDNA. 
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Figure 5.3: Normalized total gene expression in the North East UK cohort. Graph shows 
normalised total gene expression Ct values relative to reference gene. Each black circle 
represents an individual, and vertical lines represent standard error. 
5.3.2.3 Correlation ofPKP2 total gene expression with their genotypes 
Genotypes of rs 10461 16 SNP had a normal ised mean that was not statistically different in all 
genotypes. The normalised mean (N-mean) of the major allele was 15.53 ± 0.22; the N-mean 
ofheterozygotes was 15.59 ± 0.29, and homozygotes for minor allele had a N-mean of 15.3 ± 
0.819. The coefficient of correlation was r = -0.04, indicating that total gene expression had 
no correlation with the genotypes, and the p-value of this coefficient was 0.595, indicating 
that the findings were not statistically significant. Furthermore, Figure 5.4 shows a graph of 
PKP2 genotypes against PKP2 N-mean. The graph indicates that there is no influence of 
rsl0461 16 SNP genotypes on the PKP2 gene expression, as the middle line appears 
horizontal rather than skewed. 
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Figure 5.4: Effect of genotype on total gene expression of PKP-2 for rs 1 046116. The x- axis 
shows genotype for rs 1046116 SNP. The y- axis shows the normalised total gene expression 
value for PKP-2. Linear regression lines are shown as middle lines; side lines indicates the 
95% confidence interval 
5.3.3 Allelic expression imbalance 
5.3.4.1 Genotypes ofPKP-2 rsI046116 SNP 
Allelic expression imbalance studies were performed to confirm the total gene expression 
results. As the DSC2 SNP was located at the beginning of the exon, primers could not be 
designed within this region, and the DSC2 SNP had to be excluded from allelic expression 
imbalance study. A MAF of 0.19 of the PKP2 SNP, rsl046116, was obtained in this cohort 
and was not different from reported HapMap MAF in NCBI Yoruba in the Ibadan Nigeria 
HapMap cohort (YRI) (MAF = 0.195). 
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5.3.4.2 Comparison oftwo gDNA and two cDNA product peaks 
There were no spectral differences between artificial gDNA heterozygous and eDNA 
heterozygous performed to normalize the expression experiment. Figure 5.5 illustrates 
spectral peaks with their mass position indicating genotypes of rs 1046116 SNP in both 
gDNA and eDNA. This shows an accuracy of experiment and that allelic expression ratio 
analysis can be performed. 
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Figure 5.5: Spectra comparison of gDNA and cDNA quantification. The two products are 
detected and quantified by MALD]-TOF mass spectrometry. The relative mounts of each 
allele are used to quantify the amount of allelic expression imbalance using the allelic 
expression ratio (AER). The unlabeled peaks are the results of the background and spectra 
peaks multiplexed with our SNP of interest. 
5.3.4.3 Linearity and normality ofallelic expression ratios 
Genomic DNA (gDNA) from two individuals homozygous for the minor and major alleles of 
rs I 046116 in PKP2 were mixed in varying ratios (8: 1, 4: 1, 2: I, 1: 1, 1 :2, 1 :4, 1 :8). The gDNA 
of varying ratios were used as the template for the allelic expression assays to investigate the 
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appropriateness of genomic normalization ratios and the linearity of the allelic expression 
imbalance (AER) response. This experiment confirmed that allelic expression response is 
linear and that allelic expression imbalance analysis can be performed. Figure 5.6 shows a 
relationship between log AER and log mixture ratio. 
·2 
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1. y 0 .626 1>< · 0 .11 32 
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Figure 5.6: Linear relationship between measured and expected allelic expression 
ratios for alleles mixed in known ratios 
Plots of the normalised allelic ratios relative to homozygous gDNA ratio mix are shown in 
Figure 5.7. The plot indicates inter-individual variations and the figure also shows accuracy 
of the experiment at gDNA allelic ratio of 1: I. The graph revealed most individual allelic 
expression to be at zero (as expected), although there were few variations in each individual 
sample. 
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Allelic expression at rs1046116 
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Figure 5.7: Normalised Allelic expression in the cohort. The graph show 
normalised allelic ratio (x-axis) to reference homozygous gDNA 
ratio Each black circle represents an individual, vertical represent 
standard error. 
Influence ofcis-acting alleles on allelic expression 
were 54 nPT,PI"A'7\ spectra after outlier exclusions, with a mean of ­
0.03907. interval the mean intersects zero, suggesting that 
rsl046116 SNP not exert a on allelic 
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5.4 DISCUSSION 
This study demonstrated that a SNP in the PKP2 gene is expressed in the peripheral blood, 
however there does not appear to be an association between the SNP genotype and peripheral 
blood gene expressic1n, nor does there appear to be a cis-acting effect of the SNP on gene 
expression. AEI techliques are regarded to be a powerful tool to investigate gene expression 
patterns (Cunnington. Santibanez Koref et al. 20 I 0), and to date, this is the first investigation 
ARVC/OCM SNPs using samples that combine South African and British population 
individuals. 
In total gene expressIOn, our data demonstrated that there is no association between 
genotypes and gene expression in NE (UK) Caucasian cohort. Total gene expression showed 
a great variability wichin individuals, and this may be due to an influence from both trans and 
cis factors. Trans faGtors include environmental factors such as age, sex and ethnicity that 
may influence the Wly a gene can be expressed (Cunnington, Kay et al. 2009). However, in 
this case, ethnicity did appear to have an influence, since the members of this cohort were all 
of Caucasian ethnicitywhile in other genes,e.g. DSC2, there were no genotyped found. Cis 
factors can be due to some nearby cis-acting SNP that may have an influence in gene 
expression; e.g., SNPs in promoter regions and coding regions may be close enough to have 
an influence on the SNP under investigation (Pham. Bonello et al. 2012). Total gene 
expression can also be influenced by both cis-trans effects and the natural errors in inter-
individual comparisc1n. 
Allelic expression illvestigation confirmed the total gene expression results that rs 1046116 
does not have any cis-effect on gene expression. In allelic expression, inter-individual 
variability was not investigated, since the objective of this study was to investigate if the 
rs 1046116 SNP demonstrates a cis-effect on gene expression not to investigate effects on 
expression of the SNP. Because PKP2 demonstrated that expression of both alleles can be 
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measured in periphe'al blood but not DSG2, as a results the DSG2 SNP of interest had to be 
excluded from the gene expression study. To study gene expression in DSG2, cDNA would 
need to be obtained from tissues where DSG2 gene is highly expressed (in this case, the 
heart). On the other hand, DSC2 was expressed in the peripheral blood, but we lacked enough 
working material to conduct an AEI experiment. The failure of the Applied Biosytem custom 
probe assays to genotype cDNA extracted from black South Africans also contributed to the 
exclusion of the gene from AEI experiments. 
5.4.1 Limitations and future work 
To investigate both allelic and total gene expression in both PKP2 and DSG2 genes, cDNA 
from a gene-specific tissue such as heart tissue and skin tissue wi II be required in order to 
conduct an infonnative study. DSC2 appeared to be a good candidate gene for study in 
peripheral blood, bu' enough material will be required. 
5.4.2 Conclusions 
'rhe PKP2 rs 1046116 SNP does not appear to influence the expression of the PKP2 gene; 
total gene expression revealed that there might be both trans-acting regulator acting in both 
pair of chromosomes and cis-acting regulator acting on a single chromosome harbouring the 
SNP of interest (Grund berg, Small et a!. 2012). Weak expression and no expression at all of 
PKP2 and DSG2 genes, respectively, suggest that they do not have a vital function in 
circulating blood cds. These results also indicate that blood is a suboptimal source of DNA 
to study PKP2 and DSG2 gene expression. Thus the PKP2 rsl 046116 SNP does not have any 
cis-effect in blood, and blood cDNA may not be the optimal substrate to investigate innuence 
of PKP2 and DSG2 gene variations on ARVC disease phenotypes. 
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Chapter 6 
A search for known or new genes that cause ARVC by exome sequencing of the most 
promising families 
6.1INTRODUCTIOS 
In the ARVC Registry of South Africa there are 12 out of 16 (75.0%) affected families who 
do not have a disease-causing mutation in one of the five desmosomal genes (i.e. PKP2, 
DSG2, DSP, DSC2 or JUP). In this chapter, I set out to identify known or novel genetic 
causes of ARVC by ,;xome sequencing of the families \vithout evidence of a causal genetic 
mutation on routine t~enetic screening. Family ACM 8 has an autosomal recessive pattern of 
inheritance and no known causal mutation after screening five desmosomal protein genes 
(Figure 6.1). This family was prioritised for mutation screening by exome sequencing. 
Exome sequencing is a next-generation high-throughput method that uses massive parallel 
sequencing of codin:s regions of the whole genome to identify known or novel genetic 
abnormalities in a single preparation, and is a substantial improvement over Sanger 
sequencing which screens one candidate gene at a time (Feng, Tavtigian et al. 20 II). Exome 
sequencing is especially useful in recessive inheritance patterns, in which parents are 
expected to be carrie:s of the variant while affected siblings are expected to be homozygous 
for the variant (Ng, Buckingham et al. 20 10). 
Hypothesis 
I hypothesis that ACM family 8, which is consistent with an autosomal recessive inheritance 
pattern (Figure 6.1), may have a gene mutation or mutations in which both parents are 
carriers and the affecled offspring are homozygous for the mutation(s) in question. 
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6.1.1 The aim of the ~ tudy 
The aim ofthe study was to conduct exome sequencing in the most promising family without 
evidence of a caus~d genetic mutation on routine genetic screening of five desmosomal 
protein genes, in ord'~r to determine whether other known or novel genes could be responsible 
for ARVC in affected family members. 
6.2 METHODS 
6.2.1 Study participants 
A South African ARVC family of white ethnicity with no genetic mutation found on routine 
screening was selected for investigation of causative gene(s). The family underwent mutation 
screening in five de~mosomal genes (i.e. PKP2, DSG2, DSP, DSC2 or JUP), but no mutation 
was identified (see chapter 2 (section 2.4) for details of the screening methods). The study 
was performed in a family of five members (ACMS.l. ACMS.2. ACMS.3, ACMS.4 and 
ACMS.9). Both par~nts (ACMS.I and S.2) were clinically examined and did not meet the 
criteria for the diarnosis of ARVC. Two affected family members were diagnosed with 
ARVC at age 10 (ACMS.3) and 12 (ACMS.4) years. Two other sibs were clinically examined 
and were determined to be unaffected by ARVC (ACM S.9 and the first daughter, who was 
not available for blo)d sampling). 
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AC\IS.2AC\IS.l 
AC~18.9 ~ AC)'IS.3 
Figure 6.1: ACM 8 family pedigree. ACM is the disease code for ARVC in our laboratory; 
circles represent females; squares represent males; clear circles and squares represent 
unaffected family members and black circles and squares represent affected family members; 
crossed symbols represent deceased members of the family. 
6.2.2 Exome sequencing 
Genomic DNA from ACM 8.3 and 8.4 was subjected to exome sequencing; detailed methods 
are provided in chapter 2 (Section 2.7). The sequence data was further processed usmg 
bioinformatic tools to identify all variants shared by the two affected individuals. 
6.2.3 Sanger sequenc ing of candidate variants 
Sanger sequencing was used to confirm the presence of variants that segregated with the 
disease. The validation of the variants was carried out on the ABI 3100 Genetic Analyzer 
(Applied Biosystem:;) using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied 
Biosystems) and analyzed using BioEdit software (Ibis Biosciences, Carls-bad, CA, USA), 
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6.2.4 Databases used to determine the allele frequency of variants 
There were four online databases used to determine the allele frequency of variants as 
follows: 1000 Genomes (www.1 OOOgenomes.org), Exome Variant Server (EVS) 
(evs.gs.washington.~du), ARVC database (www.arvcdatabase.info) and dbSNP database 
(www.ncbLnlm.nih.gov/SNP/). These databases were used to identify whether the variant had 
been previously identified and to obtain information on allele frequency. 
6.2.5 Prediction software used to evaluate pathogenic significance of variants 
The pathogenicity of all non-synonymous rare novel variants was assessed using the 
Polyphen-2 (http://genetics.bwh.harvard.edu: 25 January 2014), SIFT (http://sift.biLa-
star.edu.sg/; 25 January 2014), and Mutation Taster 25 
January 2014) prediction programmes. Only those variants predicted to be disease causing by 
at least two of the prediction tools were considered for further analysis. The pathogenicity of 
rare synonymous variants was assessed using the RNAfolder webserver 
(http://ma.tbi.univie.ac.at/; 14 February 2014) and MutationTaster tool 
(http://w\\'W.mutaticmtaster.org/; 13 February 2014). 
6.2.6 Amplification of cDNA in heart tissue 
Heart tissue was used to verify the expression of candidate genes that were discovered in this 
study. A measurement of 20 ng of heart tissue cDNA was amplified using primers designed 
to be specific for only cDNA. The amplification methods are described in chapter 2. 
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6.3 RESULTS 
6.3.1 Exome variant caJling quality and coverage 
A total of 5798 variants were identified before filtering, and there were 13 variants predicted 
to be disease-causing and shared by the two individuals (ACM 8.3 and ACM 8.4). The 
thirteen variants were made of eight heterozygous variants (summarised in Table 6.1) and 
five homozygous variants (summarized in Table 6.2) .. 
Table 6.1: Heterozygous variants detected in the two affected family members 
Gene Gene function ,,-mino acid change 
Parvin, Alpha (PARVA) Plays a role in the organization of the actin I p.Dl3IV 
I cytoskeleton; and cell adhesion 
Ankyrin 3, Node Of Raflvier 
(AlVK3) 
Anaplastic lymphoma rt'ceptor 
tyrosine kinase (ALK) 
Deleted in lung and 
esophageal cancer 1 (DLEC/) 
WW domain containing 
Adapter with coiled-coil 
(WAC) 
HMG box domain contaming 3 
(HMGXB3) 
Neuralized homolog (Drosophila) 
(lVEURL) 
Trichorhinophalangeal syndrome 
I (TRPS I) 
, Maintenance of ion channels and cell adhesion p.R993Q 
i 
Plays an important role III the genesis and I p.1346Q 
• differentiation ofthe nervous system 
I 
Act as a tumor suppressor by inhibiting cell ! p.RSIH 
i proliferation 
Regulates the cell-cycle checkpoint p.K401E 
Activation in response to DNA damage 
Plays a role in DNA replication and repair p.E203K 
May function as an E3 ubiquitin-protein ligase to p.MISST 
activate monoubiquitination of JAG I i 
Transcriptional repressor c.-9 _-SinsT 
122 

Table 6.2: Homozygous variants detected in two affected family members 
Amino acid changeGene Gene function 
c.15009 _229-15009 _228inG 
component N-recognin 4fCBR.J) 
Ubiquitin protein ligase E3 • It regulates integrin-mediated 
signalling. 

g.331694-13551308insC 

modulator activated by bone 
morphogenetic protein. 
Glutamate receptor ionotropic I It functions as a glutamate receptor. 
SMAD family 5 (S\l1D:j It functions as a transctional 
g.6586096-656097insG 
AMP3(GRIA3) 
g. I 2233660 1-122336602insG 
Zinc finger protein 141 It is involved in transcriptional g.331694-331695insC 
(ZNFI41) regulation as a repressor 
6.3.2 Sanger sequencing validation of variants in family members 
6.3.2.1 Heterozygow: variants 
Sanger sequencing was performed in all family members to validate the variants and to 
confinn segregation with disease (Figure 6.2). 
6.3.2.1.1 Novel varil'nts 
There were three novel variants identified in ACM 8.1 (father) that were transmitted to the 
three offspring: p.R81 H in DLECI, p.E203K in HMGXB3 and p.M 188T in Neuralized 
homolog (Drosophila (NEURI)). Only p.E203K (HMGXB3) segregated with the disease in 
the offspring. Thes.! variants were also not present in the 1000 Genomes and dbSNP 
databases. They weI e also predicted to be possibly damaging by the Polyphen-2 prediction 
tool because they change amino acid groups. They were all detected in an unaffected 
individual ACM 8.9 (Table 6.3). 
6.3.2.1.2 Reported v,lriants 
There were five reported variants that were transmitted from ACM 8.2 (mother) to the three 
offspring: p.D131 V in PARVA. p.K401 E in WAC p.R993Q in ANK3 and p.R1346Q in AIK. 
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The heterozygous variant TRPS1; c.-9_-8insT was not processed further, since this variant 
was a known polymcrphism found in the dbSNP database with a minor allelic frequency of 
0.356 in 775 populati,)n individuals. 
ANK3 p.R993Q (rs J f J939315) was previously reported as a SNP, with a minor allelic 
frequency (MAF) of 0.004. This variant changes arginine (polar basic) to glutamine (polar 
uncharged). The variant was also detected in an unaffected family member. 
HMGXB3 p.E203K (rs 142114383) in exon 3 was also previously reported as a SNP with a 
MAF of 0.0038. This variant was transmitted from the father to the two affected children. 
The variant changes a glutamic acid (polar basic) amino acid to lysine (polar acidic), and it 
was predicted to be di;;ease causing by MutationTaster and damaging by the Polyphen-2 and 
SIFT prediction tools. 
NEURL p.M 188T was transmitted from the father to all offspring (including the unaffected 
individulals). The variant changes methionine, a hydrophobic amino acid, to threonine which 
is a neutral amino acid. It was predicted by MutationTaster and PoJyphen-2 to be possibly 
damaging. 
P ARVA p.D 131 V was transmitted from the mother to the affected offspring only. The variant 
is reported in the exom,~ variant server as a variant of unknown significance, and it was found 
in only one out of 12945 population controls. It changes aspartate (polar acidic) to valine 
(non-polar). 
124 
A018.2A018.1 
ACM8.9 ~, A018.3 ACM8.4 

Figure 6.2: Validation of heterozygous variants In ACM 8 family members. Gene 
abbreviations are listed in capital letters. D, aspartic amino acid; V, valine; R, arginine; H, 
histidine; G, glycine; K, lysine; M, methionine; T, threonine; E, glutamine acid; Q, 
glutamine. 
6.3.2.2 Homozygous variants 
The 5 homozygous variants shared by two affected family members were sequenced. Four of 
the variants- ZNF141 (g.331694-331695insC), SMAD5 (g.J35513085-135513086insC) and 
both variants from GRIA3, g.6586096-65866097insG and 12233660 1-122336602insG - were 
present in the unaffected sibling and therefore did not segregate with disease. UBR4 
(c. J 5009_229-15009_228 insC) was the only variant that exhibited an autosomal recessive 
pattern in the two affected family members; however this was detected in 52% of white 
population controls. All homozygous variants identified were reported as SNPs according to 
the dbSNP database. 
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Table 6.3: Reported heterozygous variants 
Gene Varianl Chromosomal 
posilion 
Amino acid change MinO!" allelic 
frequl'l1c) 
Reported/pu bl ished 
ANK3 p.R993Q, c.2978C>T chr10:61868783 
C>A 
Basic- uncharged 0.004 rs 141939315 
HMGXB3 p.E203K, 
c.607G>A 
chr5:149389968 
G>A 
Neutral- basic 0.0038 rsl42114383 
NEURL p.M 188T, c.563T>C chr1 0: 1 05331493 
T>C 
Hydrophobic-neutral - EVS 
PARVA p.DI3IV, c.392A>T 
chr11 :12495505A 
>T 
Acidic-nan-polar - EVS 
TRPSI g.50356 _50357insT 
c.-9 _-8ins.T 
Ch8:116635872 
insT 
UTR - rs35329862 
ALK p.RI346Q, 
c.4947G>A 
chr2:29416006C 
>T 
Basic-acidic Novel 
DLECI p.R81 H, c.262C>G chr3:38080978C 
>G 
Hydrophobic-uncharged Novel 
WAC p.K40IE, 
c. 1465A>G 
chr10:28905145A 
>G 
Basic-acidic Novel 
UTR: unLranslated regIOn; EVS: exome variant server 
6.3.2.3 Variants that are potentially disease-causing 
6.3.2.3.1 PAR VA: c.392A>T. p.D131 V 
The PARVA gene encodes a focal adhesion protein known as actopaxin. The variant 
identified, c.392A>T (p.O 131 V), was absent in the 1000 Genomes database but was 
identified in the exome variant server in one out of 12227 population controls. The variant 
was not observed in 232 population controls from our laboratory. This variant changes the 
polarity of amino acids from aspartic acid (D) (negative polar) to valine (V) (non-polar). All 
three bioinformatic prediction tools predicted this variant to be probably damaging. Figure 
6.3 illustrates the restriction enzyme digest (A), electropherogram (8), and conservation 
among modem species (C). 
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Figure 6.3: c.392A>T, p.D I3l V variant; A, illustrating Tsp45I restriction enzyme 
digest fragments B, an electropherogram showing an A>T nucleotide substitution; C, amino 
acid alignment showing MutationTaster conservation information of the amino acid affected . 
Ptroglodytes (chimpanzee); Mmulatta (rhesus macaques); Mmusculus (House mouse); 
Ggallus (chicken); Trubripes (puffer fish); D rerio (Zebra fish); D melanogaster (Drosophila); 
C elegans (Nematode) ; X tropical is (frogs). 
6.3. 2.3.2 HMGXB3: c.607 G>A. p.E203K 
The HMGXB3 gene encodes for HMG box domain containing 3 and this protein plays a role 
in DNA replication and DNA repair. The variant identified, c.607G>A (p.E203K), was 
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reported in the Exome Variant Server database to be present in 36 out of 4530 individuals, 
thus qualifying as a rare polymorphism. This variant was not observed in 232 population 
controls from our laboratory. The variant changes glutamic acid (E) (negative polar) to lysine 
(K) (positive polar). All 3 bioinformatic prediction tools predicted this variant to be probably 
damaging. The location where the variant is situated harbours a conserved amino acid among 
animal species; Figure 6.4 illustrates the restriction enzyme digest (A), electropherogram (B), 
and conservation among modem species (C) . 
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Figure 6.4: c.607G>A (p.E203K) variant; A, illustrating Mboll restriction enzyme 
digest fragments ; B, an electropherogram showing an T>C, which is in the reverse form 
,nucleotide substitution; and C, amino acid alignment showing conservation information of 
the amino acid affected. Ptroglodytes (chimpanzee); Mmulatta (rhesus macaques); 
Mmusculus (House mouse); Ggallus (chicken); Trubripes (puffer fish); D rerio (Zebra fish) ; 
D melanogaster (Drosophila); C elegans (Nematode); X tropical is (frogs). 
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Thus, both the PAR VA and HMGXB3 variants are possibly damaging and segregate with 
ARVC in the ACM 8 family (Figure 6.5). 
A C MS.1 ACMS.2 
HMGXB3: E203K PARVA: p.D131V 
ACM8.9 "'::CMS.3 ACM8.4 
PARVA: p.D131V PARVA: p.D131V 
HMGXB3; p.E203K HMGX83; p.E203K 
Figure 6.5: Variants segregating in ARVC family members. ACM is an ARVC identification 
code; HMGXB3 and PARVA are the relevant variants; D-aspartic amino acid; V-valine; R­
Arginine; H- Histidine; G- Glycine; K-Lysine; M- Methionine; T- Threonine; E-Glutamine 
acid; Q- Glutamine; the numbers between the abbreviations refer to the amino acid position 
in the protein. 
6.3.3 Known cardiomyopathy gene variants 
All known cardiomyopathy genes that cause ARVC, DCM and HCM were inspected for 
mutations in the exome data set. This was done by knocking out all the filters and searching 
for variants in a list of cardiomyopathy known genes. One SNP was identified in CALR3 
which is associated with familial hypertrophic cardiomyopathy (Chiu, Tebo et af. 2007). The 
SNP was not conserved, not damaging and did not affect amino acids groups. The SNP had a 
MAF of 0.008. 
6.3.4 Expression of PARVA and HMGXB3 in heart tissue 
Amplification of cDNA from left and right atrial appendages revealed that both PARVA and 
HMGXB3 genes are highly expressed in the heart, with DSC-2 used as a positive control. 
Figure 6.6 shows amplification products visualisation through ultraviolet agarose gel. 
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Figure 6.6: Investigation of HMGXB3 and PARVA expression in the heart tissue. PARVA­
Parvin alpha; DSe-2- Desmocolin-2; HMGXB3- HMG box domain containing 3; L-A- Left 
atrium; R-A- Right atrium. 
6.4 Screening of PAR VA gene mutations patients with ARVC 
The mutation in PAR VA was considered to be a more plausible candidate gene for AR ve, 
with the variant in HMGXB3 possibly playing a modifying role. This hypothesis is supported 
first by the biological plausibility of the role of PARVA in cardiomyopathy as a cell adhesion 
protein, the rarity of PARVA mutations in the general population, evolutionary conservation 
of the amino acid change and predicted deleterious effect on protein function. Whilst the 
HMGXB3 variant is likely to be a rare polymorphism, its role as a modifier gene cannot be 
ruled out given a potential digenic effect based on the inheritance pattern in this family. Thus 
HMGXB3 harbours a GVUS that was not pursued further in this study. 
Further evidence for the causal role of PAR VA mutations in ARVe was pursued by screening 
65 patients with ARVe for the presence of mutations in this gene. Two unrelated probands 
with ARve were found to have rare mutations in the PARVA gene, thus providing additional 
support for PAR VA as a new candidate gene for ARVe (Table 6.4). 
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Table 6.4: Additional PARVA mutations based on prediction tools and population 
controls screening in sixty five ARVC probands 
Illde:.; case ID '\lIckotid !\millo .\cid F:';oll 1) pc \I,\F C1a~sification Reported 
e change /illtron 
30.1 c.523A>G p.K156E 4 Missense 0.0 Pathogenic Novel 
32.1 c.597T>G p.T 199 5 Synonymous 0.0 Pathogenic rs I 11282823 
6.4.1 PARVA: c.523A>G, p.K156E 
A c.523A>G (p.K 156E) mutation, located in exon 4 of PARVA, was identified in ACM 30.1. 
This mutation was absent in all public databases and in our local population controls. The 
amino acid substitution causes a change in polarity (lysine = positive polar to glutamic acid = 
negative polar). It was predicted by the 3 prediction tools to be damaging and potentially 
disease-causing. Figure 6.7 illustrates the restriction enzyme digest (A), electropherogram (B) 
and conservation among modern species (C). 
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Figure 6.7: c.523A>G, p.K156E variant; A, illustrating Bpi! restriction enzyme digest 
fragments; B, an electropherogram showing an A>G nucleotide substitution; and C, amino 
acid alignment showing conservation information of the amino acid affected. Ptroglodytes 
(chimpanzee); Mmulatta (rhesus macaques); Mmusculus (House mouse); Ggallus (chicken); 
Trubripes (puffer fish); D rerio (Zebra fish); D melanogaster (Drosophila); C elegans 
(Nematode); X tropical is (frogs). 
The mutation was investigated in 2 other family members who had their DNA available for 
the study. ACM 30.2, a daughter to ACM 30.1 , is a carrier of the p.K156E mutation (Figure 
6.8). 
ACl\I30.3 ACM 30.1 
p .K1S6E 
ACMJO.2 
p.Kl~6£ 
Figure 6.8: ACM 30 family members with PARVA c.523A>G, p.K156E mutations. Circle: 
female, square: male, black circle/square: affected and dot in a circle/square: carrier of the 
mutation 
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6.4.2 PARVA: c.597T>G, p.T199 
A c.597T>G (p.TI99) variant, located in ex on 5 of PAR VA , was identified in proband ACM 
32.1. It has been reported in the ) 000 Genomes database as rs I ) 1282823 with no MAF 
provided; it was not found in our laboratory population controls (of note, these controls were 
screened by Sanger sequencing, since there was no restriction enzyme available for the 
variation substitution site). Although it was a silent mutation, it was predicted by 
MutationTaster to be disease-causing and by the RNAfoid webserver to change the mRNA 
structure. Polyphen-2 and SIFT were not used because they are not suitable for synonymous 
variants as it does not affect the amino acid. There were no family members available for 
screening of this variant. Figure 6.9 illustrates the restriction enzyme digest (A), 
electropherogram (B), and (lack of) conservation among modern species (C). We concluded 
that this is a variant of unknown significance (GYUS), since it is not highly conserved, rare in 
464 chromosomes, and predicted to be disease-causing. 
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Figure 6.9: c.597T>G, p.T199 variant; A, an electropherogram showing a T>G 
nucleotide substitution; B, nucleotide alignment showing mutation taster conservation 
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information of the ammo acid affected. Ptroglodytes (chimpanzee); Mmulatta (rhesus 
macaques); Mmusculus (House mouse); Ggallus (chicken); Trubripes (puffer fish); D rerio 
(Zebra fish); D melanogaster (Drosophila); C elegans (Nematode); X tropical is (frogs). 
6.5 DISCUSSION 
This exome sequencing study has identified PARVA as a new candidate gene for ARVC and 
cardiomyopathy in general. It is also possible that a rare polymorphism in HMGXB3 may be a 
modifier of the cardiomyopathy phenotype. 
6.5.1 PARVA 
PARVA encodes parvin alpha, also known as actopaxin, a protein that belongs to a series of 
focal adhesion proteins that form part of the extracellular matrix and are referred to as focal 
complexes (Clarke, Brown et al. 2004, Stiegler, Draheim et al. 20 I 2, Wehrle-Haller 2012). 
Figure 6.10 summarizes other proteins that bind to parvin alpha indicating their activation 
and inhibition proteins. These proteins link the extracellular matrix to the actin cytoskeleton 
(Kanchanawong, Shtengel et al. 20 10) in the area composite. Focal adhesion proteins bind F­
actin through adherens junction proteins, where they provide cell-cell adhesion by linking E­
cadherin to the actin cytoskeleton (van Hengel, Calore et al. 20 13). Northern blot analyses 
have demonstrated that the highest expression of PAR VA is in the kidney, heart and brain 
(http://omim.org/entry/608120). 
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Figure 6.10: Role of PARVA among focal adhesion genes. (Image taken from 
http://www.springerimages.com/Images/) . 
Parvin alpha is composed of an N-domain, two CH (Calponin homology) domains and a C-
domain. The N-domain has 95 amino acids, and while it is not involved in any interactions, it 
is a major site of phosphorylation and thus conformational change of the whole protein. The 
N-terminus contains two nuclear localization signals and three SH-binding sites. The two CH 
domains are the actin-binding sites and are separated by a linker region 
(http://omim.org/entry/608120). The CH2 domain contains a paxillin-binding subdomain 
(PBS) that interacts with an integrin-linked kinase. 
The mother of the original family under investigation (ACM 8.2) appears to be a carrier for 
the rare variant p.D 131 V. This variant (as weJl as the variants identified in ACM fami lies 30 
and 32) is located in the CHI domain (exons 3-5) and near sites confirmed to interact with F­
actin (Nikolopoulos and Turner 2000, Clarke, Brown et al. 2004, Lorenz, Vakonakis et al. 
2008). This region is highly conserved among modern animals. The structure of PAR VA and 
parvin alpha and the relevant amino acid substitutions are summarized in Figure 6.11. 
A: AC1:opaxin (PARVA) gene 
B: Parvin alpha domain st:ruct:ure 
N[.....___--'~_C~H_1--.L---...LI-:---C_H-2--~1J c 
96 t 203 263 369 
Ip _ D~31V; p_K1..5'6E & p.'T19"51 J 
Figure 6.11: Structure of PAR VA (actopaxin) gene and protein, and amino acid substitutions 
identified in ARVC patients in this study. (A) exonic structure and mutations; (B) structural 
domains. Black boxes represent exons; white boxes represent untranslated regions; N: N­
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terminal domain, CH: ,~'alponin homology, PBS: paxillin binding subdomain, C: C-terminal 
domain. D: aspartic aCid, V: valine. K: Lysine, E: Glutamic acid 
6.5.2. HMGXB3 
HlvtGXB3 gene is a mfmber of the high mobility group box family that has a DNA-binding 
high mobility group (HMG). It is thought to have a vital function in DNA replication and 
repair (Bustin 1999, R~eves and Beckerbauer 200 I). The function of this gene has not been 
previously characterised, and no studies have shown association of this protein with heart 
disease. Our expressic.n studies have shown that this protein is highly expressed in heart 
tissue and is thus likely to have an important function in the heart. The variant is conserved 
and predicted to be damaging and disease-causing by prediction tools, reported to be present 
at a frequency of less than I % in the Exome Variant Server cohort and absent in 464 
chromosomes of popllation controls. The father (ACM 8.1) appears to be a carrier for the 
rare variant (p.E203K) that was transmitted to both affected siblings. Although the variant is 
reported as a polymorphism in the 1000 Genomes database, it is possible that this SNP could 
modify the clinical expression of a latent ARVC mutation. In this case, the mechanism may 
be similar to a previously reported KCNH2 polymorphism associated with long QT syndrome 
(CrottL Lundquist et (II. 2005). Further studies could test this hypothesis. 
6.5.3. Patterns of inheritance 
In ACM family 8, neither father nor mother demonstrated the ARVC phenotype, making 
them carriers for the mutations I have identified and the pattern of inheritance a single dose of 
each parent for both PARVA and HMGXB3. Because both affected offspring inherited both 
gene mutations, it is possible that asingle dose effect from each parent exists (i.e. that one 
gene mutation is not sufficient to cause ARVC). On the other hand, when PARVA was 
screened in ARVC probands, two variants identified in unrelated probands were found, 
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suggesting that in thest individuals one mutation may be sufficient to cause disease. There 
are several lines of evidence that make PARVA a plausible candidate gene for ARVC. PARVA 
is a focal adhesion gene and there are also focal adhesion gene mutations reported to cause 
hypertrophic cardiomy,)pathy (HCM) and dilated cardiomyopathy (DCM) such as vinculin 
and metavincullin gene mutations (Vasile, Ommen et al. 2006, Vasile, Will et al. 2006) . 
Focal adhesion proteins play a role in cell-cell adhesion, a function that is akin to the 
desmosomal proteins that are known to playa causal role in ARVC. Furthermore, the variant 
that is associated with ARVC in this study is rare, having been observed only once previously 
in over 12.000 individuals. In addition, the mutation, which codes for a conserved amino 
acid, is predicted to have a deleterious effect on protein function. 
The clinical genetics of ARVC in family ACM 8 may be compatible with 3 possible 
inheritance patterns. The first is that of inherited a single dose of each parent condition. The 
results of exome sequencing have not identified a causal recessive mutation in this family. 
The second possibility is that the severe phenotype in the offspring with no discernable 
disease in the parents may be due to compound heterozygosity on the basis of inheriting 
mutations of mild effect from each parent. This possibility is supported by the transmission of 
the PARVA mutation from the mother and the HA1GXB3 from the father. However, the 
HA1GXB3 mutation a:Jpears to be a rare polymorphism, which may either have a modifying 
effect or play no role in disease causation. Finally, the disease could be due to a deleterious 
mutation in PARVA, which has incomplete penetrance in the mother. 
Compound and digenic heterozygosity have been previously noted in ARVC (Xu, Yang et al. 
2010) and compound heterozygosity was also identified in other ARVC families in our 
cohort. Two unique PKP2 mutations were identified in ACM family 19, and these mutations 
demonstrated an allele dose effect resulting in a severe phenotype in the offspring (Mbele 
2008, Watkins, Hendricks et al. 2009). Nakajima et al. suggested that compound and digenic 
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heterozygosity are mort' prevalent in ARVC patients in some ethnicities (e.g. Japan compared 
with some Western countries) (Nakajima, Kaneko et al. 2012). Others have suggested that, 
although variants may be common in desmosomal genes, they might not be sufficient in 
themselves to cause ARVC but more commonly require a "second hit" e.g. from compound 
and digenic heterozygosity, or perhaps environmental factors (Xu, Yang et al. 20 10, 
Nakajima. Kaneko et al. 2012). 
6.6 Limitations and future work 
In the present study we only screened 65 ARVC probands with no family infonnation. It is 
unknown whether PAR VA mutations are found in other cardiomyopathies (e.g. OCM, HCM). 
Future work will invove extending screening to more ARVC probands and family members, 
as well as other cardiomyopathies. Finally, functional studies will need to be perfonned for 
PARVA and H,~fGXB3 to support their causal or modifier role in cardiomyopathy. 
6.7 Conclusions 
Mutations in the PARVA and HMGXB3 genes are possible associated with the ARVC 
phenotype. and in the former case, a biologically plausible mechanism exists to explain the 
association. Future work will include validating these findings in a larger cohort of 
cardiomyopathy prob;mds and family members, and performing functional studies. 
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Chapter 7 
Summary of Findings and Future work 
7.1 Summary of findings 
I have conducted a study of the molecular genetics of arrh)1hmogenic right ventricular 
cardiomyopathy (ARVC) and dilated cardiomyopathy (OCM) in South Africans. There were 
major experiments that were performed to delineate the causal genes and the effects of 
polymorphisms on g,;ne expression in patients with cardiomyopathy. The first experiment 
surveyed the prevalence of desmosomal protein gene mutations in 65 patients with ARVC 
and 112 patients with OCM. The second experiment was concerned with the verification of a 
recurrent mutation in the plakophilin 2 gene (PKP2) as a founder mutation. The third 
experiment sought to detennine whether polymorphisms in desmosomal protein genes 
influenced gene expr,;ssion. Finally, given the lack of a known genetic cause in the majority 
of cases studied, exome sequencing was embarked upon to identify other known and novel 
genetic causes of AR VC in the South African families. 
7.1.1 Prevalence of d,;smosomal protein gene mutations in ARVC and OCM 
Fourteen of the 65 participants with ARVC had disease-causing mutations and none of the 
112 OCM patients was found to have a disease-causing mutation in the four desmosomal 
protein genes that were screened, i.e. plakophilin 2 (PKP2), desmocollin 2 (DSC2), 
desmoglein 2 (DSG~) and plakoglobin (JUP) (chapter three). In a separate study in our 
laboratory in which 150 probands with OCM were screened for mutations in the desmoplakin 
(DSP) gene, 6 (4%) individuals had a disease-causing mutation (Fish 2010)(. Taken together, 
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these data suggest that desmosomal gene mutations are an uncommon cause of DCM, and 
DSP is associated with OCM in a significant proportion of Africans. 
7.1.2 The discovery of a founder mutation in the PKP2 gene 
There were four unrelated probands (ACM 5. L ACM 12.1; ACM 19.2 and ACM 38.3) 
identified with a recunent mutation, c.1162C>T (p.R388W), in PKP2 who were investigated 
further (chapter four). The haplotype study has shown an identical mutation with a common 
haplotype which was present in 28.6% (4114) of the ARVC probands with disease-causing 
mutations in the deslnosomal protein genes that were screened in this study. The four 
individuals are white South Africans of European ancestry who inherited the haplotype 
bearing the recurrent mutation from a common unidentified ancestor. 
New index cases enti~ring the ARVC Registry of South Africa are first screened for this 
particular founder mutation. The advantage of founder mutations is that they offer the 
possibility of identifying large numbers of individuals with an identical genetic background 
for the study of genotype-phenotype correlations. 
7.1.3 Influence of polymorphisms on gene expression 
There were fourteen SNPs identified in the four desmosomal genes from participants with 
ARVC and DCM. Three SNPs with a minor allelic frequency of 2:5% were selected to 
investigate their effect on gene expression (chapter five). The three SNPs were rs 1 046116 in 
PKP2, rs868333 in DSC2 and rs 1893963 in DSG2. Due to gene expression technical 
difficulties in these experiments, only PKP2 rs 1 046116was investigated further. There was 
no association between genotype and total gene expression nor was there any evidence of 
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allelic expression imbalance of the rs 1046116 PKP2 SNP in both South African and North 
East (UK) populations. 
7.1.4 Identification of novel candidate genes for ARVC through exome sequencing 
There were also a number of families with both ARVC and OCM who did not have a causal 
mutation in desmosomll genes, and one of these families was selected for exome sequencing 
to investigate for a kne,wn or novel causal genetic mutation for ARVC (chapter six). Family 
ACM 8 had two heterozygous mutations that segregated with disease in the offspring: 
PAR VA, p.OI3IV and HA1GXB3 p.E203K. The latter was reported as a rare SNP 
(rs 142114383) with a prevalence of less than 1 %. PARVA gene encodes a-parvin also known 
as actopaxin, a focal adhesion protein, and HMGXB3 encodes a high mobility group box 
containing 3, a transcription protein. 
PARV A was prioritized to be screened in sixty five ARVC probands as it belongs to a group 
of focal adhesion pr01eins, such as vinculin and metavinculin, which are implicated in the 
causation of cardiomyopathy (Vasile, Will et al. 2006). The screening of 65 unrelated 
probands with ARVC identified two cases with mutations in PARVA that may have a 
deleterious effect on protein function. This study has established PARVA as a strong 
candidate gene for cardiomyopathy. 
7.2 Future directions 
This work has laid the foundation for at least four directions of research in South Africa. 
First, I have shown tllat desmosomal protein gene mutations account for a minority (about a 
fifth) of cases of ARVC in South Africa which is much lower than the proportion of up to 
50% found elsewhere in the world. Therefore, there is a need not only to screen for non-
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desmosomal gene causes of ARVC, but also for a major effort to identify hitherto unknown 
genetic causes of ARVC and OCM. Numbers of persons diagnosed with ARVC will also be 
influenced by the threshold for diagnoses and the other factors. This may also playa role in 
finding mutations and tne proportions with specific mutations. 
Second, the discovery ,)f a founder effect provides the basis for the extension of the existing 
families to establish a large panel of individuals with ARVC due to the same genetic cause. It 
is likely that the four families identified in this thesis from a likely common founder is a 
fraction of carriers of the disease-causing mutation in South Africa.The ascertainment and 
phenotyping of these family members will provide a resource for genotype-phenotype studies 
of ARVC. 
Third. r have shown in a proof of principle study that desmosomal protein genes, such as 
PKP2. are expressed in peripheral blood. Although the exonic variant in PKP2 had no effect 
on whole gene expression or allele specific expression, there is a need to study a large 
number of polymorph isms and variants of unknown significance by this method. This study 
has shown that it is possible to study gene expression of desmosomal protein genes reliably in 
peripheral blood, alth,]ugh ideally heart tissue should be used for these experiments. 
Finally, I have discO\ ered strong evidence supporting the role of PAR VA as a candidate gene 
for ARVC. The screening of large numbers of cases of ARVC and other cardiomyopathies, 
and functional studi.:!s of the impact of PARVA mutations are required to establish the 
causality of this varilnt. In addition, the potential role of mutations in HMGX3 as modifier 
genes for ARVC reqllires further study. 
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Appendix 2: Solutions and Buffers 

lOX Tris Borate EHTA (TBE) buffer (2L) 

216g (O.89M) Tris base (leN Biomedicals, Inc.) 
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110g (0.89M) Boric Acid (ICN Biomedicals, Inc.) 
l4.8g (0.5M) Ethylenediaminetetraacetic acid, pH 8.0 (Merck) 
Made up to 2L with dHzO 
Agarose Loading Dye solution 
0.125g (0.25%) Bromophenol blue 
20g (40%) Sucrose (Calbiochem) 
Made up to SOml with dH 20 and pH adjusted to 8 
1X Buffer 0 solution (for 100% MboII digestion) 
SOmM Tris-HCL (pH 7.5) (Promega) 
lOmM MgCI2 (Merck) 
100mM NaCI (Sigma-Aldrich) 
O.lmg/ml Bovine Serum Albumin (Thermo Scientific 
1. 1X Buffer Tango solution (for 100% Nsp/ digestion) 
33mM Tris-acetate (pH 7.9) 
lOmM Mg(C2H30 zh (Sigma-Aldrich) 
66mM CH 3COOK (AnalytiCals) 
O.lmg/ml Bovine Serum Albumin (Thermo Scientific) 
Appendix 3: GeneRuler™ 100bp DNA ladder Plus 
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App(!ndix 4: Desmosomal gene designed PCR primers 
Table 1: PKP2 primer sequences used and PCR product sizes for each exon 
Primer peR products Size (bpi Primer sequence (5'-3') 
Annealing 
Temperature (0C) 
1-1F 
263 
ACT CGA GCG GGG CGG GGC TCG C 
681-1R GCG GC CAG ACA GTC AAG AGC CTG 
1-2F 
268 
GTC CTG GGC CAG CAG ATC CTG 
55 
1-2R CTC ACC CCG CGT GCT GGG AGT 
2F1 
203 
GCC TAC TTG TAT TCT GAG TT 
53 
2R1 CTA GTG ATC AGA TTA CTA CCA TG 
3-1F1 
231 
CAG AAA GGG GCA AAC TTC TCG 
58 
3-1R1 AAG GTC CTT GAG GCA TCC TC 
291 
CTC TCA TGT GCA GGC TGG C 
55+2F 
2R GAC ACA TAC CAC AGA CAG TAC 
3-3F 
273 
GAT ATG CTC GTT CCG AGA TC 
55 
3-3R GTC CTC CTG GCA TCA GAG 
3·4F 
236 
GTC ACT CAG AAC AGG G 
55 
3-4R I GCA GTT CAG TCA TTG CCA G 
4F 
291 
AGT ATT CGC TGA GTC GTC TCT 
55 
4R CTT CTA TTA TGG TGA CTT TGC 
5-1F 
272 
GAA AGG TTA TAG TCA GCA TCA G 
55 
5-1R GTA CCT CGG CTG CTC CAG GTG 
5-2F 
250 
CGT TCA GCG AGC TGT GTG 
57 
5-2R TCC TGG AGC AAA TGA TTG ATG 
6F 
258 
TTG CTG TGT TCA TAA AGG AGC C 
55 
6R GTC GTG GTC TGC GCC TGT AAT 
7F 
291 
GGT CCC ACC CTG CAC TGT m C 
58 
7R GT A GCC CCA AGG AAG TCA G 
8F 250 CAA AGA CCT GTT GGA TAC ACA 58 
8R ATT CTT AAG ATA GCC GCT TGG 
9-1F 
305 
TAC TCA TTG CAT TTC CCC CAG 
57 
9-1R GAT GTT TTG GCA GTC GAA GCA G 
9-2F 173 GCA TTC TTC ATA ACC TCT CCT AC 55 
9-2R GGG AAG TTT TTG AAA GAA TG 
10-1F 
222 
CAG TAT TTC TGG TCT CCT GG 
58 
10-1R CGC AAC TAC ACA CAA GAA GCA TCC 
10-2F 
218 
GGA GGA AAA GAG CAA CCC CAA G 
58 
10-2R GTA GAC ATA CCT ACA TTC AAT TC 
11-1F 
191 
CAT CAA CCT CTG GTA ATC TAC G 
60
11-1R CCA AGT GTG AAA AAG ACA GCC ATC 
1l·2F 
219 
CTC AGA CAG TTG TCC AGA AG 
56
11-2R GTT GTC TGT ATC ACC TCC CG 
12-1F 
210 
GGG ATCTTG GGA TTA AGAAAC AAT C 
62 
12-1R GAA TGC ACG CGA CCT TCT AAA C 
12-2F 
187 
CAG CCT CTG CCT GTT ACA CAT TG 
59 
12-2R GTG TGT AAA TAA TCC GGT TG 
13F 
149 
CCC TGA TeT CAG AAT GTC C 
53 
13R GAA CAA GGA ATG TGT CAT AG 
14F 
240 
GTT ACC TTT CAC GTT TCT G 
56
14R GTG GTC CCC TGA ATC CAG AA 
*Number (e.g. 9) denotes the exon; F= forward primer, R= reverse primer 
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Table 2: DSG2 primer sequences used and peR product sizes for each exon 
peR product Annealing 
Primer 
size (bp) Primer sequence (5'-3') temperature (Oc) 
CTITGGGTIGGGCTGGGCTGIF 59351 
CGCCCTTGTGCGCGTTAC1R 
2F CTGAATIGAGCAGTAAATIGGC 55167 
GTIGACTGGGCmACTAGi 2R 
GAA GCC TCA TAG GAAATACG~ 3F 58337 GTG TGA GAG GAC TTI TAT GTCi 3R 
CAA CTC CAC TGC CAT TCC CCi 4F 53298 
GTA GTI TIT CTG TCA TAA TAA G4R 
CATAGTATG GTAATITAGmTC5F 
51275 
CTITATCCCCAC TGTAAATAAAC 5R 
6F CAT TCA CGC TIA TGT CCT CAT C 
54399 
6R TCC TTICCA GTI TCT CCT CTC 
7F GGA CTA AAA CCA GAA AGC CAG 
59345 
7R GCA GCT TGA AGG GAT GGT TG 
8F CAA GCT CAA GTI CAG ATI CG 6011 55 
8R GAT TCC TTI CCA GCA CCA AC 
9-lF TCC TGT GCA TIA AAT TAT TGT ATC 
5028i 
9-1R GCA GCG TCA TCT CAA m ATG 
9-2F GAA GAA T CTT GAC TIC AGT G 38!, 54 
9-2R CAAAAG GTC TAC AAG TIAAATTTI CC 
10F GAAAGAGCTGTAGATGTTAGAGG 30' 60 
lOR CCAACATCAGAAACCATTGAmGATIG 
llF GGCAAGGGAATICAAACTATG 
43il 58 
llR GGAGTTTATGAAATGAGGTCCTG 
12F CATITGTGGAATITAATGTTGCCTC36,\ 55 
I 12R AGTGCACTCCTGGAGATG 
I 13F GTGAAGACAAGTCCAGGAAGG 
5431\ 
13R GTGTTTCTTACATGTTIGGTIGI 
14-1F CCAAGGATGAAGGATICCCTC 59262 
14-1R GTAGAGCTACCCAGTTIACAGG 
14-2F CAACATGAGATGTCCGAGATG 
286 52 
14-2R GTATGTGAATGTGATATIATTAGGG 
1S-1F GAC CCA GGC AAA CTI CAG 
313 56 
15-1R CAG TCC AGT TGT GTC GTA GG 
15-2F GCT TCT ATI GGT TGT TGC AG 
310 53 
15-2R CAT AGT TTG CTC ACA GAG TG 
L 15-3F GAG CAG AGA CAA AAA CCT G 573c 3 
I 15-3R CAG TGG TIG GTG GCA TAG 
15-4F CAC CTC TIC CTG ACC CAA TG 
350 53 
15-4R GTC ACA TIC TGT CCT ACT GC 
I5-5F GAA TCC TCT GGA AGG CAC TC 553(.2 
15-5R GCA GCA TCA TCT CTA TGT C 
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Table 3: DSC2 primer sequences used and peR product sizes for each exon 
peR product Annealing
Primer 
size (bp) Primer sequence (5'-3') Temperature (0C) 
CTA AGA AAA GCA CCT CTC CGCIF 
54461lR GTG CGC TGA nA CAT CTA CC 

2F 
 GGA GGA AGC TAG AAC TCA G 
536792R GTG GGG AAC AAC ACA AGT G 

3-1F 
 GAA nTTAA GTT nT GGCTCT CCC 
223 523-1R cn CTC nc TCC GAG GAC 

3-2F 
 GGA GGA TGG nc AGT CTA TAC 
259 53 
GCC TCA TGG Tn TCA TTC GTC 

4F 

3-2R 
CTG AGA GGA GAA AGA TGT GTC 
269 514R GTG TCA TAA TGG TAA GAG ATG G 

5-lF 
 GGA GAA CTA AGA TGC ACT AC 
335 505-1R ~GTA CAA TAC AAG Tn CCA G 
5-2F GGA Gn GAC CAA GAA C 
233 535-2R CTA nA GGG AGT AGC CAG AGC 

6F 
 CAG TCT CCA AGT TAA AGC C 
320 516R CTG CTT CTC AAC GGA CAT AG 

7F 
 CTG TAT GGA GAG GTC TGC 
516927R CCA GAG An AGA GAG ACA TAA AC 

8F 
 GCT GTG AAA TGT AAT AAT GCA C 
334 568R CAA cn nA ATG TeA CTG GGG CAC 

9F 
 GTG CTA GGG TTT CAA ATC ATG 
540 559R CTG GGC TAG GAA AAG TCT GG 

lOF 
 CGT GGTTATTCC CAA CAT G 
554 51lOR CTC TCT ATC CAG GCT TCT G 

llF 
 GAA ACA AGA AGT AGC AGT GG 
475 51llR GCT ATT AGA AAG CAG ACA TGA G 
CAG TGC ATA CnTTGTGG TG 
211 52 
GGA TAG GCT CAT CAG GAT C 
CTG CAA ACC CAC CAT GTCHBi 5228812-2R CAC TAG AGA GAC CTA CTC CC 

13F 
 GCC ATC CCA TCA GGA ATA TC 
621 5313R GAT AGA GAC TGG CCT GGC 
14F GAC ACA AGC AAT CCA GGA AAG C 
397 5614R CAG GGG ACC CAT GAC ATT C 
15F GTT TCC ATA GTT GGG TAT GC 
901 5115R CAC GCA TGT GGC AGC AAG 

16F 
 GAA TeC ATT AGA GGA CAC ACT C 
615 5116R GGC TGT TGT CAT TAT ACC C 
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Table 4: JUP primer sequences used and peR product sizes for each exon 
Primer 
peR product 
size (bp) Primer sequence (5'-3') 
Annealing 
Temperature (0e) 
1F 
lR 
186 
GTCTCTTCGCCTTTTGTTCGGT 
61 
CTG TCC CCA ACG ATA CCT G 
2-lF 
2-1R 
199 
CCT TTG TGC CCC CAG TAG 
60 
GTG GTT TTC TTG AGC GTG TAC 
2-2F 
2-2R 
184 
CAGCAGCAAGGGCATCATGG 
58 
CAG AGA CCC CCT ACA ATe 
3-1F 
3-1R 
22, 
GTT TGG GCA GGG CAA GAG 
59 
GTG GCC AGC AGA AGC GAG 
3-2F 
19: 
GAGTACCAGATGTCCACAAC 
53 
3-2R GCTCAAGTCGGCCATTGT 
3-3F 
21(, GCTCAAGTCGGCCATTGT 56 
3-3R CAT ACC CTT CCA CAG AGC TGA 
4-1F 
29'1 
GAG AGC AGA TGT CCT CAG 
58 
4-1R GTG TCC AGG TCG CTG GTA nc 
4-2F 
23,; 
GCT GTC GTG CGT ACC ATG C 
62 
4-2R CAC TGG ATA TTT ATG GAA GCT 
5-1F 
341 
CAG AAG CAG GAG GAG TCA nG 
57 
5-1R GAT AGA AGA TGG CGC AAG GGT G 
5-2F 2n CAT CTC ACA CTC ATT CCC TC 54 
5-2R CAC CCT TGC GCC ATe TTC TAT C 
6F 
28) 
GCG CTT CCT TGT TeC TGT CA 
53 
6R GGA GCA TGG CTG ACT GAG 
7F 
279 
GAGGCTGGTGAGTATGATG 
56 
7R CAG ACA GGA GGC TGG ATG 
8F 
20 
cn GGA CAT ATT CGA GAA GG 
59 
; 8R CGT GAT GTC GTC CTT GTC 
9-1F 
2C 5 
CTT CAG ATG TCC AAG AAG TGC 
55 
9-1R CGT GTA GGG CTG CTG TGT G 
9-2F 
2-1 
CTC GTC CAA CTG CTG GTG AAG 
58 
9-2R CCA TGA CAG CCG AA T GAA C 
10F 
2"9 
CCA TGT CCA AGG CAC CTG 
51 
lOR CTC CAA AGA CCT CTT GAT AC 
11-1F 
2~)7 
GAC GGC CCA TTT TCC ACT ATG 
55 
l1-lR GAG TGC AGC AAC TCC ATG AGT 
11-2F 
2;l9 
GTG GAG AAC ATC CAG CGC GTG 
56 
11-2R GGT AGT CTG GGT TCT TGT C 
12F 
2·,8 
GAG GCT GGC CGA CGT TTA AC 
58 
12R CTA TGA AGTTGA CAG TAG TAG 
13F 
2 )4 GAG CCT GCA TTT TeA AAC CTC 60 
13R CGG AGC CTG CAT TTT CAA AC 
14F 
135 
GAC CGA GCC CCA cn TTT GTC 
58 
14R CAA AGA GGG GGC CGT ACT 
170 

Table 5: PARVA primer sequences used and peR product sizes for each exon 
Primer peR product 
size (bpI Primer sequence (5'-3') 
Annealing 
Temperature (0C) 
1-lF 
247 
CAG CTC cn CCA GGG CAG AG 
621-lR GTC GCC nc TGT CCC CAA GTC 
1-2F 
417 
CGT nG GAA AGC CGC AGC CTC AG 
631-2R CGA CGC GCA CCC CAC ACT GAG 
2F 
225 
TGT TAC AGA GCT CCA ACC CC 
602R GCT GGC ATG GGA AAG CTT AA 
3F 
210 
CACGATGCTGGGTAACTGTG 
593R CTCACTGACCCACCATGTG 
4F 
242 
GCT GGT CTG TAA GAA AAT ACC CC 
604R CAC ACA TCC An GCA GCA CT 
5F 
246 
GCA TGC AGT AGG Gn GTC TG 
605R ATG GAT GGCnCTTG GGG AA 
6F 
243 
TGC CTA GAA CCT GGA AGA AGA 
586R GAC CTACTC GAC GCA CCA TA 
7F 
250 
CAG GAA TGC TCA TCA GTG Tn C 
607R TCC CTC CTG CAA TCC CAA TA 
8F 
201 
CAA TAA nG GAG GCC GTG CA 
558R TGA GAG CCT GTT CCT CCC A 
9F 
241 
GAG GCTTCCCAT CGG TAG n 
589R TCC CAA TGT TCT Gn GCA TCT C 
10F 
240 
TCC TCT GCT nc ACC CTC AC 
60lOR AGA nc CCA TGC CCT CAT CC 
llF 
250 
GGT AGG CIT CAG GTG GCA TA 
52llR TCC CIT GAT GTC CCT TCT CC 
12F 
207 
TGC TGG GCT CCT TCA cn C 
5712R TGC nc CCT CTG CTA CAA AAT C 
13F 
238 
GAA GGG AGG GGC AGT GTA TG 
5513R GTA AGG CAG nc GGA GGA GG 
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